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ABSTRACT
Valve disease is a specialized form of cardiovascular disease that specifically affects the
heart valves. Heart valves serve the vital function of maintaining unidirectional blood flow
through the chambers of the heart during the cardiac cycle; however, as valve disease progresses,
this function can become severely compromised [1]. Currently, the only cure for valve disease is
to replace the defective valve with an engineered substitute. Each year, over 300,000 heart valve
replacement surgeries are performed worldwide [2], and this number is expected to continue
growing as life expectancies increase [3].
In the United States, the most common form of valve disease is aortic stenosis [4], which
can become severe enough to necessitate valve replacement surgery. Although the demand for
replacement valves is growing, current clinically available valve substitutes have still not been
perfected. Mechanical valves present problems with thrombosis and necessitate lifetime
anticoagulation therapy, whereas bioprosthetic valves have limited durability [1, 5].
Furthermore, valve replacement surgery is very invasive, and high risk patient populations are
often denied surgery. Over 50% of elderly populations with aortic stenosis are not offered
surgery because the mortality risk is too great [6, 7].
Due to the limitations of traditional heart valve replacement surgery, a new, less invasive
option, percutaneous aortic valve replacement (PAVR), has been developed [8, 9]. PAVR
involves transcatheter delivery of a crimped, stented valve to the aortic annulus. The valve is
deployed by a balloon catheter or self-expansion. While not yet commercially available, two
percutaneous heart valves (PVRs) are currently in clinical trials [9]. These models are composed
of glutaraldehyde-fixed pericardial tissue.
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A major limitation of PVRs is the diameter to which the stent can be crimped. The
device profile precludes use in small or tortuous vascular systems, limiting the candidate patient
pool for PAVR [10]. An alternative material for PHVs may be porcine vena cava, as this tissue
may provide enhanced flexibility and resilience. This study evaluates the feasibility of utilizing
vena cava as a bioprosthetic tissue in PHVs by comparing its structural, mechanical, and in vivo
properties to those of bovine pericardium. While the extracellular matrix fibers of pericardium
are randomly oriented, the vena cava contains highly aligned collagen and elastin fibers that
impart strength to the vessel in the circumferential direction and elasticity in the longitudinal.
Mechanically, the vena cava is significantly less stiff than the pericardium, even after
crosslinking with glutaraldehyde (GLUT) or combined neomycin and glutaraldehyde (NG)
protocols. Furthermore, the vena cava‘s mechanical compliance is preserved after compression
under forces similar to those exerted by a stent, whereas pericardium is significantly stiffened by
this process. However, the high elastin content of the vena cava may be responsible for
enhanced calcification as compared to the pericardium, and an effective anticalcification strategy
is necessary if the vena cava is to be clinically useful. Taken together, these results suggest that
the vena cava may enhance leaflet flexibility, tissue resilience, and tissue integrity in PHVs,
ultimately reducing the device profile while improving the durability of these valves.
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CHAPTER ONE
INTRODUCTION

1.1. Heart Valve Anatomy and Physiology
In order to create a viable replacement valve, a thorough understanding of heart valve
function and structure is required. Any successful prosthesis will have to withstand the dynamic
operating environment and adequately reproduce natural valve function.

1.1.1 Valve Function
The cardiovascular system is composed of the systemic and pulmonary circulation. The
pulmonary system is responsible for oxygenating the blood, while the systemic circulation
carries this oxygenated blood to the body‘s organs. The heart, which is the muscular pump that
provides the force necessary for blood flow, has four chambers which collect and distribute the
blood. Additionally, four valves within the heart open and close to allow for unidirectional
blood flow through the circulatory system. The tricuspid and mitral valve are between the atria
and ventricles. The pulmonary valve controls blood flow from the right ventricle to the
pulmonary artery, while the aortic valve controls blood flow from the left ventricle to the aorta
[1]. The mechanical action of the valves is controlled by pressure gradients within the heart
chambers. All of the valves open and close once per cardiac cycle, totaling more than 3 billion
cycles in a lifetime [1]. A schematic of the cardiac anatomy is given in Figure 1.1.
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Figure 1.1: Anatomy of the heart valves [1]

1.1.2 Tissue Structure and Function Correlation
The aortic valve is the most frequently diseased and transplanted valve, likely because the
great pressure and forces required to pump blood from the left ventricle throughout the entire
body [5]. The aortic valve is also the most widely studied, and the valve of greatest interest to
our lab; thus, further discussion will focus specifically on this valve.
Replacement valves intend to mimic the natural function of the heart valve, and
bioprosthetic valves further aim to replicate the native valve structure as well. The structure and
function of the aortic valve are highly correlated. The aortic valve opens during ventricular
systole to allow blood to pump into the aorta. As blood fills the aorta, the aortic pressure rises.
Once a critical backpressure is reached, the aortic valve closes and remains completely closed
during ventricular diastole [5]. The valve is composed of three cusps or leaflets, which coapt
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(contact) during valve closure to prevent leakage. The unique architecture of the cusp tissue
prevents the leaflets from collapsing and allows them to withstand cyclical deformations and
stretching [5].
The heart valve cusps are composed of three tissue layers: the fibrosa, ventricularis, and
spongiosa. The fibrosa, located on the aortic face of the cusp, is composed of circumferentiallyaligned, crimped collagen fibers. The collagen fibers impart strength to this load-bearing layer
[11]. The ventricularis is located on the blood inflow surface, which faces the ventricle. This
layer is predominantly composed of radially-aligned elastic fibers that allow for flexibility and
elastic recoil of the cusps [1, 12]. Between these two layers is the spongiosa, a highly
hydrophilic layer composed of loose connective tissue with abundant glycosaminoglycans
(GAGs) [13]. The gel-like matrix of the spongiosa acts as a lubricant and shock-absorber to
reduce shearing between the other two layers [1]. They also aid in diffusion of oxygen and
nutrients through the valve tissue, which is largely avascular [14].
This complex, multi-layer architecture renders the leaflets highly anisotropic, but
promotes smooth valve opening and closing [5]. The crimped fibers make the valve much more
compliant in the radial direction than the circumferential. As the valve closes, the crimps expand
radially to allow for elongation and coaptation without great stress on the tissue. The extended
collagen fibers impart stiffness to prevent cuspal sagging or collapse [5]. The elastin fibers
recoil during valve opening to decrease the dimensions of the cusp and maximize blood flow
through the orifice [15]. The shear stresses generated by these movements are dissipated by the
spongiosa [5]. A diagram of the valve architecture during ventricular systole and diastole is
shown in Figure 1.2.
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Figure 1.2: Structure of the aortic valve during ventricular systole and diastole [5]

1.2 Heart Valve Biomechanics
1.2.1 Hemodynamics
Aortic valve disease preferentially affects the fibrosa, which is on the aortic side of the
leaflets; it is thought that complex fluid flow and shear stress profiles cause this phenomenon
[16]. Computational fluid flow models have been used to study the dynamics of blood flow on
both the aortic and ventricular sides of the cusps. While the valve is in the open position, flow
on the ventricular side is smooth, straight, and accelerating due to the pressure from ejection.
Flow through a healthy valve reaches a peak velocity of approximately 1.2 m/s [16]. However,
on the aortic side a rapid increase in cross-sectional area due to the aortic sinuses causes a large
change in the pressure gradient that results in more disorganized flow. While the valve is
closing, the flow on the ventricular side remains relatively straight, while the flow on the aortic
side becomes increasingly chaotic [16]. The flow fields of a fully open and a closing aortic valve
are shown in Figure 1.3.
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As the valve is closing, the pressure gradient between the ventricle and aorta causes flow
reversal across the leaflets. Once the valve is fully closed, vortices occur behind the leaflets to
facilitate more quick and efficient cusp movement to the fully coapted position [17].

Figure 1.3: Fluid flow in a fully open valve (left) and closing valve (right). [16].

1.2.2 Mechanical Testing
In vitro testing is a valuable tool for assessing the biomechanical properties of heart valve
tissue. Four types of mechanical tests are commonly used: uniaxial, biaxial, flexure, and fatigue.
Each method gives different types of information about the valve properties, and they are often
used in combination to fully characterize the tissue response to loading.
Uniaxial testing was widely used in the past to quickly record basic information about the
tissue mechanics. During this test, thin strips of tissue are stretched until failure. Physical
properties such as elastic modulus and ultimate tensile stress are obtained. Additionally, cycling
the load rather than loading until failure can be performed to produce hysteresis curves.
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However, uniaxial testing does not simulate physiological conditions, as the valve experiences
forces in all directions in vivo. Thus, uniaxial tests are inadequate to fully describe the tensile
response of the tissue [2, 18].
In order to overcome the limitations of uniaxial testing, biaxial tests were introduced.
Equibiaxial testing simultaneously exerts equal force in the radial and circumferential directions.
Multi-protocol loading schemes were also adopted [19] to characterize the tissue when varying
loads are applied in each direction. Biaxial testing allows one to calculate stiffness and
extensibility values for leaflets that have been loaded in ways that better mimic physiological
stress patterns. Areal strain is a measure also commonly used by Sacks et al. to characterize the
change in cusp area due to the applied biaxial tension [2].
Flexure is defined as the bending or curvature of the valve leaflets. During flexure, each
layer of the cusp is loaded differently; for example, the fibrosa may be in tension while the
ventricularis is in compression. Flexure is generally examined with a three-point bending
apparatus [20] and the cusps are marked with graphite markers to visualize the deformations.
Each test specimen is bent with its natural curvature and against its natural curvature, and the
stiffness and strain responses are observed [18].
Finally, fatigue testing is used to measure the valve‘s response to simulated cardiac
cycles. The valves are mounted in silicone tubes in a chamber that pumps fluid through the
system in a periodic fashion that replicates pulsatile blood flow. Accelerated fatigue tests are
performed at a rate of approximately 1 million cycles per day, allowing researchers to simulate
years of valve function in a matter of months. After the valves are fatigued, they undergo other
assays to characterize how the tissue responded to the cyclic stresses. For example, biaxial
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testing may be repeated to determine how fatigue alters tissue stiffness [18]. It has been
suggested, however, that the accelerated ―heart rate‖ used in fatigue testing alters the loading
pattern on the valves, since the leaflets are not closed for as long as they would be
physiologically and thus do not experience peak stresses for the same duration [18]. While this
may be true, in vitro fatigue testing provides invaluable information about valve durability and
tissue response to simulated functional conditions, and eliminates the need for large-scale animal
studies to investigate valve dynamics or to screen valve prostheses. Fatigue testing can generally
be considered a reliable method for assessing a valve‘s mechanical performance under
physiologic flow conditions.
1.2.3 Heart Valve Loading Response
Over the cardiac cycle, the aortic valve experiences several types of forces. Three basic
modes of loading have been characterized: tension, flexure, and shear [2]. Flexure, which is
defined as bending or curving of the cusps, occurs during opening and closing of the valve.
Shear occurs when blood flows through the valve orifice. The valve is in tension when it closes
and must resist the backflow of blood from the aorta. The valve leaflets are fully loaded and
unloaded during each cycle, which is in contrast to other tissues, such as blood vessels, which are
preloaded, but do not experience significant loading cycles. Additionally, the cusps stretch
significantly in response to small pressure changes during valve closure. Peak strains as high as
1000% have been observed. Once the valve is closed, deformation ceases, but the leaflets must
withstand peak stresses of 50-100 N/m [2].
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1.2.3.1 Tension
The unique cuspal architecture facilitates movement and enables the valve to endure the
imposed stresses. The valve experiences the highest loads when it is closed and must bear the
stress of blood backflow. The collagen in the cusp plays a large role in withstanding the imposed
tensile forces. The alignment of collagen fibers is highly correlated to the directional
extensibility and strength of the leaflets. Collagen is very strong under tension, but cannot
withstand high torsional or compressive loads. The direction orthogonal to collagen alignment
will be more compliant, whereas the direction parallel to the collagen fibers will be able to resist
more tensile stress [21]. The circumferential alignment of the fibrosa collagen leads to higher
compliance in the radial direction than in the circumferential [22]. Higher peak stretch has been
observed in the radial direction (1.7) than the circumferential (1.02) [18].
As the valve is strained, the crimped collagen fibers straighten and rotate toward the axis
under tension [2, 23]. Fully aligned collagen helps to prevent cuspal prolapse, while also
transferring load to the aortic wall [21]. The tight, angular distribution of collagen fibers leads to
a highly anisotropic leaflet with a high degree of coupling between the radial and circumferential
directions. As the valve closes, the radial axis is loaded in tension, which causes the collagen
fibers to rotate and leads to contraction in the circumferential direction. As the ratio of radial
load to circumferential load increases, negative strains in the circumferential direction may be
observed. Ultimately, the radial loading is opposed by the circumferentially-aligned collagen
fibers of the fibrosa, and high radial strains result [2]. Work has been done to separate the
contributions of the fibrosa and ventricularis in load-bearing. The two layers were carefully
peeled apart, and then each was subjected to mechanical testing. It was observed that the
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ventricularis dominates the radial response while the fibrosa dominates the circumferential
response [16]. At full leaflet deformation, the ventricularis experiences twice the stress level as
the fibrosa [2]. Furthermore, it was also observed that the spongiosa contains fibers that can
couple the two outer layers [16].

1.2.3.2 Flexure
Flexure is the natural leaflet bending that occurs during opening and closing of the valve.
During flexure, the three distinct tissue layers experience different forces and strains [2]. As
mentioned earlier, flexure testing allows one to discern the individual contributions of each tissue
layer to the applied stress. When the cusp is flexed in the direction of natural curvature, the
ventricularis is in tension and dominates the stiffness response, whereas the fibrosa is in
compression so the collagen fibers contribute little. When the cusp is bent against its natural
curvature, the situation is reversed and the ventricularis is in compression while the fibrosa is in
tension; thus the collagen fibers contribute highly to the observed stiffness in this case [2].
The cuspal commissures, the region where the leaflets come into contact with each other
and with the aortic wall (Fig. 1.4), experience very high flexure during valve opening. When the
valve is fully opened, the flexure angle is 65° in this area [24, 25]. The collagen fibers in the
commissure region are more aligned than in the belly region and also align more rapidly under
pressure [20]. However, the stiffness at the commissures is about 1/3 that of the belly stiffness.
The stiffness at the commissures decreases with increasing opening angle to reduce the opening
force. The stiffer belly region may facilitate smoother cusp movements and prevent wrinkling of
the tissue [24].
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Figure 1.4: Cuspal commissures [24]

Flexural stiffness is thought to play a large role in valve durability. Large curvature of
the tissue may be a failure mode of bioprosthetic valves. After 50 million fatigue test cycles,
equivalent to 1.5 years of valve function, a significant loss of flexural rigidity is observed [18].
Geometrical changes in the cusps may occur during valve opening and closing, possibly resulting
in kinks or buckles in the tissue, especially at areas of high curvature. Buckling is due to local
collapse of the tissue, which presents histologically as notches (Fig. 1.5). Vesely et al showed
that the higher the curvature of the cusp during fatigue cycling, the greater the depth of the
buckles in bioprosthetic valves [12]. Thus, the ability of the cusps to flex smoothly is just as
vital to proper function as the ability to bear load.
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Figure 1.5: Example of tissue buckling [27]

1.2.3.3 Shear
Heart valve cusps experience complex shear forces that are generally not as well
understood as the tensile and flexure stresses. During normal valve function, shear helps to
reduce compression, tension, and tissue buckling [26, 28]. Shear strain is an internal slippage
mechanism. The more shear the tissue experiences, the greater the decrease in bending stiffness
during flexure, allowing the valve to open more smoothly with less internal stresses and less
tissue buckling [29]. While the tensile properties of the cusp are dominated by the strongest
layer, the shear response is dominated by the weakest layer, the spongiosa [29]. The spongiosa
layer of the tissue is thought to work as a lubricant to facilitate slipping between the fibrosa and
ventricularis [30]. Loss of the GAGs in the spongiosa can lead to increase stiffness due to
internal bonding between the ventricularis and fibrosa. Contrarily, loss of spongiosa can also
lead to delamination of the tissue layers [31, 32].
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The shear properties of the cusp can be observed using uniaxial or biaxial testing. Shear
stress versus shear strain curves can be plotted to calculate the hysteresis, which is a measure of
viscous loss in the tissue [29]. Other viscoelastic properties, such as creep and stress relaxation,
have also been studied in native valve cusps. Results show that cusps undergo high stress
relaxation but little creep during three hour tests. Stress relaxation is thought to be due to the
internal slipping between layers, which is modulated by GAGs and proteoglycans. The lack of
creep behavior suggests that sliding can only occur under constant strain, not constant load.
Thus the valve is able to withstand loading without time-dependent effects [2]. The functionality
of the viscoelastic responses is still not completely understood, but it appears that shear between
the tissue layers may help dissipate stress in the cusps.

1.3 Heart Valve Disease

Heart valve disease generally presents in one of two ways: improper closure of the valves
which can lead to backflow (regurgitation) or incomplete opening of the valve (stenosis) [1].
The causes of valve disease are conditions that lead to alterations in the structure of the valve
tissue, which subsequently cause malfunction. For example, valve disease is often associated
with congenital defects, infections such as endocarditis, rheumatic fever, or atherosclerosis [33].
Thickening of the valve tissue can occur due to carcinoid heart disease or use of certain drugs,
such as the diet supplement Phen-Fen [21]. Endocarditis and rheumatic fever can destroy the
valve tissue and lead to regurgitation, whereas atherosclerosis leads to plaque formation and
calcification that can cause stenosis or tears in the tissue [33].
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Figure 1.6: Example of a diseased heart valve [34]

Valve disease is irreversible and may be fatal if left untreated. Pharmacological agents
cannot prevent valve disease or help to repair damaged valves, as valve tissue is unable to
spontaneously regenerate [1, 35]. Thus, heart valve replacement surgery is the only current
clinically available treatment. This procedure is traditionally performed by open-chest surgery,
but there has recently been a push to develop a substitute valve that can be delivered
percutaneously, reducing the trauma to the patient [9]. In either case, the diseased valve is
replaced by a mechanical or bioprosthetic substitute, which is intended to restore proper valve
function.

1.4 Mechanical Valves

1.4.1 History and Design Evolution
Mechanical valves have been used in valve replacement for over 50 years. In 1952,
Charles Hugnafel implanted the ball-and-cage valve into the descending aorta [36]. Shortly
after, major advances in surgery, such as the advent of the heart-lung machine, allowed for open
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chest surgery, with the first valve replacement surgery performed in Sheffield, England in 1955
[36]. These events sparked an era of major innovation in heart valve prostheses. During the
1960‘s and 1970‘s, the mechanical valve prosthesis evolved dramatically, from the early balland-cage valve to a tilting disc model to the bileaflet design. Improvements in materials
accompanied the design changes to produce safer and more effective valves.
The ball-and-cage valve was first used in the descending aorta to treat valvular
insufficiency, but did not replace the native valve. In 1960, Albert Starr and Miles Edwards
improved the ball-and-cage valve so that it can be implanted in humans (Fig. 1.7) [37, 38]. The
first models were made with stainless steel, but soon a cobalt-chromium alloy and later titanium
became the material of choice for the cage. The ball was made from silicone. While this model
was used for a number of years, improvements in the understanding of fluid dynamics and valve
mechanics revealed that the design had poor hemodynamic properties. In a native valve, central
flow is unimpeded, thus there is no loss of pumping energy and blood flow is efficient.
However, in the ball-and-cage model, central flow is entirely impeded, leading to unnatural flow
patterns, turbulence, and vortices [36]. Additionally, thrombus formation and tissue overgrowth
also occurred in some patients, leading to valve failure [39].

14

Figure 1.7: Starr-Edwards ball-and-cage valve [37]

To address the shortcomings of the ball-and-cage valve, the tilting disc model was
developed in the 1970‘s (Fig. 1.8). The tilting disc valve is composed of a housing ring which is
covered with a fabric sewing ring to facilitate implantation. A single strut and central pivot axis
allow the disc to rotate in response to pressure gradients to open and close the valve orifice. The
opening angle of the tilting disc is of extreme importance, as higher angles reduce transvalvular
pressure gradients and lead to superior hemodynamics [36]. This model was an improvement
over the ball-and-cage valve, as the tilting disc allows for partial central flow. A number of
companies developed tilting disc models, and many acquisitions and buyouts ensued. In the late
1970‘s Pfizer took over Shiley and redesigned the Bjork-Shiley tilting disc valve. However, the
redesigned valves suffered huge mechanical failures due to fracture at the outflow strut [36, 40,
41]. The valves were removed from many recipients. The cause of the failures was clarified in
1984. Apparently, over-rotation of the disc caused transient impact and bending stresses that
were in excess of the valve‘s fatigue limit [36]. Following this disaster, strut and pivot designs
were improved to reduce erosion and load impact. Today tilting disc valves are still
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commercially available and manufactured by both European and American companies, including
AorTech, Medical CV, Medtronic, and Sorin Biomedic [37].

Figure 1.8: Medtronic Hall tilting disc valve [37]

While the tilting disc valve offered superior hemodynamics to the ball-and-cage valve, a
major breakthrough came in 1977 when St. Jude Medical introduced the bileaflet valve (Fig.
1.9). The bileaflet valve improved central flow through the valve and also increased the valve‘s
effective orifice area to 2.4-3.2 cm2, as compared to 1.5 to 2.1 cm2 in the tilting disc [36]. If the
leaflets are aligned parallel to the blood stream, central flow is almost entirely unobstructed,
offering hemodynamics similar to the natural valve. During the 1980‘s St. Jude‘s bileaflet valve
became the most commonly implanted mechanical valve prosthesis. The bileaflet model has a
number of advantages over the tilting disc, including improved flow, lower transvalvular
pressure gradients, reduced turbulence, increased orifice area, and lower risk of
thromboembolism [42]. The introduction of this model in 1977 marked the end of major
innovations in mechanical valve prosthesis; only incremental improvements have been
introduced since then.
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Figure 1.9: Edwards Lifesciences bileaflet valve [37]

Along with major design modifications came improvements in material choice, as well.
The early ball-and-cage valves were composed first of stainless steel, then cobalt-chromium
alloy, and then titanium. It was soon observed that pyrolytic carbon used in atomic reactors was
stronger and had reduced cracking. When tested in biological environments, it also showed
reduced incidence of thrombosis [36]. Since the 1970‘s, all mechanical valves have used
pyrolytic carbon either as a surface coating or to construct entire housings and leaflets. Titanium
is still used for valve housing in some models. Many bileaflet models include leaflets of
pyrolytic carbon coated onto a graphite substrate that is doped with tungsten to allow for
radiographic imaging. Originally, silicone was added to the carbon to increase wear resistance
and strength, but pure carbon was found to produce a 50% stronger material and provide a
smoother surface finish [36]. In addition to the housing and leaflet material, the sewing ring
fabric is also a design consideration. Since the ball-and-cage model, sewing rings have been
made from Dacron, PTFE, or PET. These materials facilitate implantation and also allow for
tissue ingrowth and incorporation of the prosthesis into the annulus, which helps to prevent
leakage [37]. Recently a thin coating of pyrolytic carbon has been added to the sewing ring for
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surface smoothness and controlled tissue growth. Sewing ring porosity, weave, and flexibility
have also been modified to increase ease of implantation [37].

1.4.2 Current designs
Many of the aforementioned mechanical valve prostheses have been discontinued as
design flaws are revealed or improved models are introduced to the market. However, a number
of bileaflet models and a few tilting disc valves are FDA approved and commercially available in
the US.
Although the bileaflet model has become the most commonly implanted mechanical
valve prosthesis, the Medtronic-Hall tilting disc valve is still occasionally used. This valve
features titanium housing and a pyrolytic carbon disc. The sewing ring is made from knitted
PTFE or knitted PET in the EZ-Fit version. The Medtronic-Hall valve encourages more central
flow than other tilting disc valves because it has a high orifice to annulus ratio. The cage
material is free of welds and bends, which reduces the risk of thrombosis, and the central disc
can rotate, allowing for even wear across the surface [37]. In fact, one study revealed that the
Medtronic-Hall tilting disc valve reduced turbulence and increased hemodynamic performance
as compared to some bileaflet valves [43], making this model competitive with the latest bileaflet
technologies.
Since its introduction in 1977, the bileaflet valve has gained the favor of surgeons and is
the most widely implanted mechanical valve. FDA-approved bileaflet valves are manufactured
by four companies: St. Jude Medical, CarboMedics by Sorin CarboMedica Inc., Medical Carbon
Research Institute (MCRI), and ATS Medical [42]. All of the valves made by these companies
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utilize the same basic design, but minor differences in materials or features differentiate each
model. Most design modifications focus on maximizing the orifice area for a given annular size,
in order to minimize outflow gradients and produce efficient, unimpeded flow.
St. Jude offers the Hemodynamic Plus (HP) line and the newer Regent model. Both are
composed of two pyrolytic carbon semi-circular discs in a pyrolytic carbon housing and Dacron
sewing ring. The Regent model has a modified, low-profile sewing ring that allows a larger
valve to be implanted into a small annulus. Additionally, the Regent valve may be implanted
into the supra-annular rather than intra-annular position, another feature which allows for large
valves to be implanted into smaller annuli. Thus, the Regent increases the effective orifice area
and may provide better hemodynamics for a given annulus size [42].
The CarboMedics valve was introduced in 1986. It is made from pyrolytic carbon and
has no pivot guards or struts, which helps to reduce blood flow impedance. A titanium ring
around the valve housing allows for rotation to the optimal position after implantation [37]. The
sewing ring is pliable and cork-shaped, which may decrease the risk of perivalvular leaks.
Additionally, the CarboMedics Top Hat model was the first mechanical valve prosthesis
designed specifically for supra-annular implantation [37]. Because the supra-annular space is
less restricted, the surgeon may size up the implant one size larger than that which would be
implanted intra-annularly. However, the CarboMedics valves have a smaller opening angle and
slightly taller vertical profile than other valves, which may increase transvalvular pressure
gradients and impede aortic closure [42].
The ATS bileaflet valve is similar to the St. Jude models. Its main design modification is
that the pivot area that holds the hinges is not a cavity, but rather reverses outward into the blood
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stream to allow better washing of the hinges and decreased stagnation, which may reduce the risk
of thrombosis [44]. ATS also boasts that the valve has a lower-profile than others and reduced
noise upon closing [45].
Finally, MCRI manufactures the On-X bileaflet valves. These have the largest opening
angle (90°) of any valve on the market. They are made from pure pyrolytic carbon, with no
silicone additives, which increases surface smoothness and decreases thrombogenicity. The
valve is implanted supra-annularly, with a flared housing extending into the annulus. The flared
design may minimize tissue in-growth near the leaflets while also improving hemodynamics by
increasing laminar flow and decreasing hemolysis [46, 47]. Furthermore, a small amount of
regurgitant blood flow is built into the design to improve washing of the hinge surfaces, thus
reducing the risk of thrombosis [42].
All of these mechanical valves have proved durable in clinical studies for up to 25 years
[42, 48]. The bileaflet valve will likely remain the mechanical valve standard, with minor design
modifications aimed at reducing thrombosis and maximizing the effective orifice area.

1.4.3 Complications and failure modes
While mechanical valve prostheses have excellent long-term durability and
hemodynamic properties, they also have several drawbacks. The most serious and prevalent
complications associated with mechanical valves is the risk of thromboembolism. Foreign
bodies, such as implants, in blood-contacting positions activate the blood-coagulation cascade,
which can lead to clot formation (thrombosis) and possibly embolism if the thrombus becomes
immobilized. Blood trauma and platelet activation may result from high shear stresses or
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turbulent flow. The blood coagulation cascade ensues, leading to the production of thrombin and
eventually a fibrin clot. Because the prosthetic surface is not endothelialized, clots are
predisposed to form at the surface. Thrombosis generally initiates in areas of stagnation, such as
around hinges and pivots [36]. To reduce thrombus in these areas, valves are designed to allow
backwash of blood over the surface to help clear the surface of adherent platelets and clot
materials [36, 49, 50]. With ball-and-cage valves, the incidence of thromboembolism was 4.5%
per patient year [36, 51]. That statistic has been lowered to 0.6%-2.5% with the tilting disc and
1.1-3.7% in bileaflet valves [52, 53, 54]. While design modifications and material selection may
help to mitigate thrombosis, the risk remains. Thus all patients receiving mechanical valves
require life-long anti-coagulation therapy [36].
The American Heart Association recommends mechanical valve prostheses for patients
under the age of 65 who can tolerate anticoagulants [42]. Indeed, mechanical valves are
routinely implanted into pediatric patients and young adults because of their high durability. In
the past there was a concern that a second replacement would be needed as the young patient
grew, but new, supra-annular designs with large orifice areas may eliminate that limitation.
However, the need for lifetime anti-coagulants remains the greatest weakness of mechanical
valves. Proper anti-coagulation therapy with Coumadin (Warfarin) minimizes the risk of
thrombosis, but bleeding complications such as hemorrhage may result [36]. The incidence rate
of intracranial hemorrhage is 0.8%-3.7% per year in prosthetic valve patients [55]. At a ten-year
follow-up, 15% of St. Jude Medical valve recipients had been hospitalized for hemorrhaging
[56]. Furthermore, certain patients cannot tolerate anticoagulant therapy or should not be put on
it because of comorbidities, possibility of pregnancy, or insufficient access to anticoagulants
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[42]. Because anti-coagulation therapy presents such a major limitation to mechanical valve use,
companies are attempting to design their valves to minimize thrombosis and decrease the dosage
of anticoagulants required. Clinical trials are currently underway in patients receiving low or no
anti-coagulation therapy, but results will not be available until 2013 [42].
In patients who follow proper anti-coagulation therapy, the most common cause of valve
failure is pannus overgrowth, which causes obstructive failure in 31-53% of cases [57, 58].
Excessive tissue growth into the sewing ring can narrow the orifice or cause leaflet
immobilization [36]. The cause of tissue overgrowth is not completely understood, but the
inflammatory response is thought to play a large role. A chronic foreign body response to the
sewing ring causes macrophages and giant cells to remain at the valve site. These cells release
cytokines and growth factors that can signal a hyperplastic tissue response [59]. New valve
designs have attempted to prevent overgrowth from interfering with the leaflets by making the
housing cylinder longer or tapered to act as an in-growth barrier. Furthermore, coating the
sewing ring with a thin layer of pyrolytic carbon may also help to attenuate excessive growth
[36].
Major failure modes of mechanical heart valves are related to the aforementioned
complications. Catastrophic mechanical failures such as leaflet immobilization, strut fracture,
and valve immobilization have largely been eliminated by design modifications. CarboMedics
valves boast a 95% freedom from valve-related mortality over 10 years, while St. Jude Medical
reports a 93% freedom from mortality [60]. The need for secondary replacement of the valves is
less than 2% over the 25 year period [48]. The durability of the mechanical valve has not been
matched by any biological tissue valve prosthesis, making the mechanical valve preferred for
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younger patients. New technology will aim to reduce the risk of thrombosis and the reliance on
anticoagulants to improve the safety of these prostheses.

1.5 Tissue Valves
1.5.1 Types
Tissue-based heart valves, which are composed of fresh or preserved human or animal
tissue, have been used since the early 1960‘s [5]. Over the years, tissue valves have become
increasingly popular and are currently used in over 50% of valve replacements [61]. There are
three categories of tissue heart valves: allograft, autograft, and xenograft.

1.5.1.1 Allografts
Allografts are defined as tissue that has been transplanted between members of the same
species [5]. Heart valve allografts are obtained from cadavers and cryopreserved without
undergoing any crosslinking. The tissue is protected during storage by freezing it in dimethyl
sulfoxide to prevent ice crystal formation. The valves are stored at extremely low temperatures,
usually -196°C in the vapor of liquid nitrogen [5]. Cryopreservation of the fresh tissue has
several advantages, such as enabling a long shelf life and the possibility of a valve banking
system. To commercialize such a product, however, the quality of the preservation process must
be carefully monitored, as factors like freeze/thaw cycles and the interval between death and
harvest can impact the valve‘s viability.
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The allograft valve can be implanted in a number of ways, including into the aortic root
without a stent as an isolated valve or with a full root replacement. Allografts that have been
implanted into the aortic and pulmonary positions do not cause an immune response and exhibit
excellent hemodynamics and a low risk of thrombosis, even without anticoagulation therapy [62,
63, 64]. However, allograft valves, like all tissue valve replacements, are subject to material
deterioration, and their durability is limited by progressive degeneration. The main failure mode
of allograft valves implanted into the aortic position is tissue incompetence, generally presenting
as cusp rupture or perforations [5]. Although the allograft valve has not been crosslinked by any
cytotoxic chemicals, valvular cells are not viable after the valve has been transplanted. It is
hypothesized that cells are lost due to ischemia during harvest, the cyropreservation technique,
and ischemia during surgery. These events may signal the cells to undergo apoptosis and cause
massive loss of viable valvular cells [65]. Because of this cell loss, the implanted valve cannot
grow, remodel, or produce active metabolic functions [66]. Fatigue failure ensues because the
valve cannot repair the injuries that occur due to normal repetitive functioning. One year after
implantation, the allografts exhibited flattened and thinned cusps, with no evidence of collagen
crimping or corrugations. The three-layer tissue structure is not well defined and there are no
obvious endothelial or interstitial cells [5]. The cusps generally do not calcify, but aortic wall
calcification may be severe. Longer-term implants show similar trends, with no viable cells and
calcification occurring around cellular debris. While the collagen fibers are preserved, they are
distorted and lose crimp, much like crosslinked bioprosthetic valves. The allograft heart valve
shows slightly better durability than the bioprosthetic valve (50-90% survival at 10-15 years for
the allograft as compared to 40-60% for the bioprosthesis) [5]. However, allograft valve success

24

is greatly limited by the ability to preserve the extracellular matrix and prevent degenerative
tissue damage.
1.5.1.2 Autografts
Autograft heart valves are prepared from the patient‘s own tissue. The most common
type of autograft heart valve replacement is the Ross procedure, which was first performed in
1968 [5]. The surgery entails replacing the patient‘s aortic valve or entire aortic root with his
own pulmonary valve [67]. The pulmonary valve is hemodynamically superior to any other
replacement valve that may be put in the aortic position. This procedure is often performed in
young patients, as it is possible that the pulmonary valve will remain viable and grow with the
somatic growth of the child [68]. The transplanted pulmonary valve is generally replaced by an
allograft pulmonary valve. The allograft performs better in the pulmonary position than in the
aortic position because pressures and stresses are less in the pulmonary circulation than in the
systemic. The cusps of the aortic autograft have been shown to retain their normal ECM
architecture, and viable cells have been observed up to six years after implantation [5].
However, the aortic wall may suffer inflammation, scarring, or necrosis after the procedure.
Furthermore, the pulmonary artery will experience greater pressures in the aortic position than in
the pulmonary position and is not perfectly adapted to function there. Progressive remodeling of
the pulmonary wall occurs, leading to progressive dilation of the valve lumen [67, 68].
However, the autograft option is still in use for young patients, since it may help to avoid
secondary replacements as the patient grows.
A second type of autograft valve is made from the patient‘s pericardium. During surgery,
a piece of the pericardium is excised and fixed briefly in glutaraldehyde to stiffen it and facilitate
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handling. The tissue is then cut with a special die and mounted on a two-piece stent that snaps
together to hold the leaflets [69]. However, it was found that significant scarring occurred when
the pericardial tissue was subjected to high hemodynamic forces in its new environment [70].
The brief glutaraldehyde immersion mitigated this problem, but added additional concerns about
leaflet stiffness and potential calcification. Results of early clinical trials were variable, with
some valves lasting for years and others failing quickly due to leaflet tearing and prolapse [70].
Because of design issues and uncertain results, this procedure never gained wide popularity and
has largely been abandoned.
1.5.1.3 Xenograft
Xenograft tissue is transplanted from one species into a patient of a different species.
Xenograft heart valves are commonly referred to as bioprostheses and are comprised of animal
tissue that has been preserved in some way, usually by chemical crosslinking [5]. While a
number of crosslinking methods have been used experimentally, including β-propriolactone,
glycerine, β-irradiation, polyepoxides, and photooxidation [1, 5, 71, 72,], fixation with
glutaraldehyde is the method used in all commercial valves. Two types of heart valve
bioprostheses are available: intact porcine aortic valves or valves crafted from bovine
pericardium (Fig. 1.10)
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Figure 1.10: A porcine aortic valve (A) and a bovine pericardial valve (B) [70]

The cardiovascular system of pigs is similar to that of humans; thus the porcine aortic
valve can be successfully transplanted between species. The glutaraldehyde-fixed valve is
generally mounted in a stent or a sewing ring before implantation. Glutaraldehyde diminishes
the immunogenicity of the foreign tissue, nearly eliminating the risk of immune rejection [5].
Glutaraldehyde also preserves structural elements such as collagen. The porcine heart valve
contains the same three-layer, oriented tissue structure as the human valve. However, fixation in
glutaraldehyde causes many alterations in tissue chemistry and mechanics, and over time the
cusp architecture is damaged by fatigue. Valve durability is limited, and 50% fail within 12-15
years [73, 74].
Bovine pericardial valves differ from porcine bioprostheses in a number of key ways.
Bovine valves are comprised of glutaraldehyde-treated parietal pericardium which has been cut
into cusps and attached to a frame. While porcine valves are constrained to the normal tricuspid
shape, the design of bovine valves is much more flexible, and unicuspid and bicuspid valves are
possible [75, 76]. However, pericardial valve fabrication may also affect durability. The porcine
aortic valve is naturally intact, but the pericardial valve is trimmed and attached to a stent. The
attachment points may be weak areas that have a higher risk of tearing. Also, the trimmed
surfaces at the inflow and free edge of the cusp usually exhibit collagen splaying during function.
Loss of integrity at the edge may facilitate an influx of host cells and fluid, which could have
implications in inflammation and calcification [5]. Despite these complications, the bovine
pericardial valve remains an attractive option, especially for new technologies like percutaneous
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valves, because it offers greater design flexibility than the porcine aortic prosthesis. Pericardial
valves also offer better hemodynamics than the porcine aortic xenograft valve. While the
porcine valve naturally coapts due to radial extensibility caused by collagen alignment, the
pericardial collagen is unoriented, so the cusps do not naturally coapt. Thus, a coaptation
mechanism is built in: the three leaflets are fabricated as three sections of a cylinder and are
aligned parallel to the blood flow. During closure, the three edges of the cylinders are pressed
together and during opening, the cylinders reverse curvature and snap open to reveal a wide,
circular orifice [70]. This coaptation mechanism imparts excellent hemodynamics, but can also
be a weakness of pericardial valves. If one leaflet experiences greater stresses and stretches
more than the others, it may prolapse slightly so that the three leaflets do not align and seal
together properly. Single leaflet prolapse is a major cause of early cusp rupture in bovine
pericardial valves [70]. However, as both porcine and bovine valves have advantages and
disadvantages, both models are commercially available and used clinically today.

1.5.2 Current bioprosthetic designs
Several types of bioprosthetic heart valves are FDA-approved and commercially
available. Porcine, bovine, and autograft valves are all currently implanted. The models differ
by fixation procedures, anti-calcification treatments, and use of stents. Figure 1.11 classifies
today‘s clinically available valve prostheses.
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Figure 1.11: Classification of bioprosthetic valves [77]

Bioprosthetic valves are broadly separated into two categories: stented and unstented.
Most first and second generation bioprosthetic valve models are mounted on a stent, which is
made from plastic or a metal, such as a cobalt-nickel alloy [77]. The stent is additionally
covered in a Dacron skirt, which prevents stent thrombogenicity and facilitates implantation by
sewing. The stent also renders the valve easier to handle and minimizes the surgical duration.
However, the stent and the sewing fabric both take up space in the annulus, leading to a smaller
orifice area that may lead to residual stenosis [77]. Additionally, the stent may restrict aortic
wall expansion and contraction, leading to abnormal hemodynamics [70]. Thus, stentless valves
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were adopted in many third generation bioprostheses. Edwards Lifesciences manufactures the
Carpentier-Edwards stentless bovine pericardial valve. Several stentless porcine valves are also
marketed, such as Edwards Prima Plus, Medtronic Freestyle, and St. Jude Medical‘s Quattro and
Toronto valves [77]. Stentless porcine valves are fabricated by excising the entire aortic root and
aorta, and trimming it to the desired profile. A Dacron cloth may still be included around the
base. Because the stent has been eliminated, there is more room in the annulus for a larger valve
to be implanted, thereby increasing the effective orifice area of the valve. The movement of the
prosthetic valve in the annulus is less constrained and improved hemodynamics have been noted.
However, significantly more aortic wall is exposed to blood flow than in the stented valves, and
aortic wall calcification has been a major limitation of the stentless model. Rapid calcification
after implantation causes the root to stiffen, eliminating the advantage of greater flexibility [70].
The benefits of stentless valves are highly debated and clinical outcomes are widely variable
[78]. Thus, stentless valves have not replaced stented valves, and the choice of implant is based
on the surgeon‘s preference.
Prosthetic valves also differ in fixation mechanism. While all valves are crosslinked with
glutaraldehyde, the concentration and duration of the treatment varies slightly between
companies [5]. Additionally, the back pressure applied to the valves during fixation can also be
a factor in valve performance. First generation valves were fixed under a pressure of 80 mmHg,
which is equivalent to systolic blood pressure [70]. However, it was later discovered that highpressure fixation produces cusps that are very stiff and subject to significant tissue buckling
during functioning [16, 18, 26]. Fixation pressures as low as 4 mmHg can produce these
detrimental effects. Consequently, in the 1980‘s, low-pressure fixation was used in second-
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generation valves, producing more flexible valves with improved mechanical properties [70].
Zero-pressure fixation has also been used, for example in Medtronic‘s Intact valve [79]. These
valves only coapt when back pressure is applied. Furthermore, when the aortic root is
depressurized, its elastic fibers recoil and the orifice collapses by about 35%. This leads to
excessive leaflet area in the annulus, which may be obstructive during valve opening [11]. A
solution to this problem has been to fix the leaflets at zero pressure while pressurizing the valve
root at approximately 40 mmHg [70]. This technique is employed by Medtronic in its Freestyle
and Mosaic valves [80].
Finally, bioprosthetic valve manufacturers use anti-calcification technology to
differentiate their products. Calcification of the cusps and aortic wall is a critical factor in tissue
deterioration and valve failure [77]. Medical device companies aim to improve the durability of
their valves by reducing the risk of calcification. Medtronic treats its valves with 2-alpha-aminooleic acid (AOA), which binds to the tissue to inhibit calcium influx [81]. However, AOA has
been shown to only prevent calcification of the cusps, not the aortic wall. To address both cuspal
and aortic calcification, St. Jude Medical uses a two-part treatment on its valves. The valves are
first treated with aluminum chloride which prevents aortic wall calcification and then with an
ethanol solution, which prevents cuspal calcification [82]. Edwards Lifesciences, on the other
hand, uses a proprietary process called XenoLogiX to remove calcification-initiating
phospholipids from the tissue. The treatment is a combination of ethanol and polysorbate-80,
which is a surfactant [83]. The mechanisms of action of each of these treatments will be
discussed below. Each method has been successful at reducing calcification and extending the
average lifetime of the prostheses.
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In summary, the current market for bioprosthetic heart valves is dominated by three
major companies: Medtronic, St. Jude Medical, and Edwards Lifesciences. Each company offers
stented and stentless valves. St. Jude and Medtronic deal mainly with porcine aortic valves
while Edwards offers both porcine and bovine models. All of today‘s models employ
glutaraldehyde fixation under low back pressure. Thus, the main feature differentiating each
company‘s valves is the anti-calcification technology.

1.5.3 Complications and failure modes
While bioprosthetic heart valves have benefits over mechanical valves, such as being
nonthrombogenic and eliminating the need for anti-coagulation therapy, they are not as durable
as the mechanical model, and progressive tissue degeneration is the main failure mode [5]. Over
half of bioprosthetic valves fail in adults 10-15 years post-implantation [73]. In patients less than
35 years old, and especially in children and teenagers, tissue deterioration and failure occur much
more quickly due to a stronger immune response and higher metabolic activity [1]. Bioprosthetic
valve failure is generally caused by four major complications, which may act alone or
synergistically: endocarditis, calcification, mechanical malfunction, and pannus overgrowth [77].

1.5.3.1 Endocarditis
Infective endocarditis can affect both mechanical and bioprosthetic valve implants. The
risk of infection is greatest in the first two years after implantation and is more common in
patients who have previously experienced endocarditis [77]. The incidence of infection is
approximately 1-6%, and a multitude of microorganisms, including Streptococci, Staphylococcus
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epidermidis, Gram-negative bacilli, and fungi, have been reported to cause endocarditis [77, 84].
Infection usually begins in the sewing ring and then spreads to the cusps, potential leading to
tears and valvular insufficiency. Endocarditis is diagnosed based on the presence of
microorganisms, vegetations, fibrosis, necrosis, and calcification. In addition to valvular
incompetence, the infection can cause congestive heart failure and embolism, and has a 60%
mortality rate if valve replacement surgery is not performed [85]. However, infective
endocarditis is an acute condition that affects a limited subset of patients and is not considered a
major cause of long-term tissue degeneration and valve failure.

1.5.3.2 Calcification
Calcification is one of the main causes of valve failure (Fig. 1.12). Approximately 75%
of porcine valve degenerative failures present as regurgitation due to tears in calcified cusps.
Pure stenosis due to calcification causes failure in 10-15% of valves. Tears and perforations
unrelated to calcification cause calcification in only 10% of valves [86]. Thus, calcification is a
major factor in valve performance and durability.
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Figure 1.12: Calcified heart valve prosthesis [77]
It is generally accepted that four main factors—glutaraldehyde, cellular injury, matrix
composition, and mechanical stress—are responsible for pathologic calcification of bioprosthetic
heart valves [87]. Glutaraldehyde-induced devitilization of the tissue leads to loss of cellular
calcium regulation, which has a significant impact on calcification potential [88]. In healthy
cells, the intracellular calcium concentration is approximately 1000 times below that of the
extracellular calcium concentration. The gradient is maintained by energy-requiring processes
such as calcium ion pumps [88]. Glutaraldehyde is cytotoxic and devitalizes the valvular cells.
Following glutaraldehyde fixation, all energy-requiring processes, including calcium regulation,
are eliminated. Studies show that glutaraldehyde permeabilizes the cell membrane, causing
intracellular calcium levels to increase in a dose-dependent manner immediately after
glutaraldehyde exposure [87]. Since the cell‘s natural calcium pumps are not functional, the cell
cannot extrude the extra calcium, and intracellular calcium concentrations increase dramatically.
Phosphorous concentrations are normally greater inside the cell than outside, but
glutaraldehyde fixation also causes an influx of phosphorous. When intracellular concentrations
of calcium and phosphorous reach sufficiently high levels, nucleation of hydroxyapatite crystals
occurs [87]. Phospholipid-rich bodies, such as the plasma membrane and organelles, are
nucleation sites for calcification [88]. The calcium deposits at each nucleation site grow larger
and eventually can converge into nodules that stiffen and weaken the tissue [86].
In addition to devitalized cells and cellular debris, extracellular matrix proteins, such as
collagen and elastin, have also been implicated in calcification [86]. However, glutaraldehyde is
likely also responsible for matrix calcification, since non-glutaraldehyde-treated tissue and Type
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I collagen sponges do not calcify in vivo [89]. When glutaraldehyde devitalizes the tissue, it
removes cellular components, exposing matrix sites for mineral nucleation [89]. Loss of matrix
material from the fixed tissue over time may also contribute to mineralization. For example,
glycosaminoglycans (GAGs) are not stabilized by glutaraldehyde. GAG degradation may
expose calcifiable sites in the extracellular matrix, leading to further nucleation [90].
Furthermore, calcification and mechanical stress may work synergistically to cause tissue
deterioration. Calcification is generally enhanced in areas of high mechanical stress [86, 87].
Cyclic deformations may allow a greater influx of calcium ions, as well as calcium deposit
migration and aggregation in deformed areas [87].
The extent of calcification is highly variable among patients, although calcific deposits
can often be seen histologically within three years of implantation [77]. Pathologic calcification
can produce disastrous consequences, such as severe tissue stiffening, stenosis, and cuspal tears.
Due to the prevalence of calcification-related valve degeneration, most commercially available
bioprosthetic valves undergo anti-mineralization treatments. Medtronic valves are treated with
two-alpha-amino oleic acid (AOA), a detergent that binds to residual aldehyde groups to become
incorporated into the tissue. AOA works by altering calcium influx kinetics, significantly
inhibiting the penetration of calcium ions into the tissue. Furthermore, AOA disrupts the
interactions between calcium and phosphorous, thereby suppressing crystallization [91].
However, the aortic wall is resistant to AOA penetration, and its calcification potential is not
significantly decreased by AOA. Thus, AOA is effective only in inhibiting cuspal calcification
[86]. Similarly, the method of ethanol pretreatment, used by both St. Jude Medical and Edwards
Lifesciences, is only effective on the cusps. Ethanol extracts phospholipids and cellular debris
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from the valve tissue, thus reducing the number of available mineralization nucleation sites [92].
Edwards Lifesciences combines the ethanol with polysorbate-80, a surfactant that also targets
phospholipids. Edwards XenoLogiX treatment of ethanol and polysorbate-80 is reported to
remove 95% of phospholipids from the valve tissue [83]. While this greatly reduces the cellrelated calcification that is prevalent in the cusp tissue, aortic wall calcification may still be
problematic. Thus, St. Jude Medical additionally treats its valves with aluminum chloride.
Metal ions such as iron and aluminum can complex with phosphate ions and prevent binding of
calcium, thus inhibiting calcium phosphate crystallization [5]. Aluminum chloride also binds to
elastin to cause a structural change which renders the molecule resistant to crystal deposition.
Since the aortic wall has a high elastin content, aluminum chloride treatment is especially
effective at limiting calcification at the wall [1,5]. Currently, St. Jude Medical is the only
company whose anti-calcification treatments target both the aortic wall and cusp tissue. While
each of the aforementioned treatments are clinically effective in reducing pathologic
calcification, none can completely eliminate mineralization; thus, calcification-related tissue
degeneration remains a major contributed to failure of third-generation heart valve prostheses.

1.5.3.3 Mechanical malfunction
While cuspal tearing and structural degradation are often associated with calcification,
material degeneration can occur independently of mineralization. The bioprosthetic heart valve
experiences great stresses during valve function and must endure over 30 million loading cycles
per year [1]. Over time, stress-induced material fatigue can lead to disruption of the extracellular
matrix structure, resulting in loss of tissue integrity, tears, perforations, and ultimately
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mechanical failure [93]. Additionally, enzymatic activity can mediate degradation of certain
structural components [30]. Since valvular cells are devitalized by glutaraldehyde fixation, the
tissue structure is entirely dependent on the integrity and preservation of the extracellular matrix
components, such as collagen, elastin, and glycosaminoglycans. As the valves lack viable cells,
there are no repair or regeneration mechanisms in place to reverse damage once it occurs.
Material deterioration by fatigue and proteolytic enzymes is a progressive process, and damage
accumulates during valve functioning. Thus, valve durability is largely determined by the
quality of the preserved matrix.
Flexure stress is hypothesized to play a large role in valve durability. A loss of flexural
rigidity is observed after approximately 50 million in vitro fatigue cycles, equivalent to 1.5 years
of function [18]. Although tissue fixation with glutaraldehyde causes an undesirable increase in
leaflet stiffness, loss of flexural rigidity in fatigued tissue can also be problematic. The observed
increase in flexural compliance may be due to alterations in the tissue structure, such as
debonding of collagen fibers or a loss of glycosaminoglycans [32]. Indeed, there is evidence for
glycosaminoglycan loss in fixed tissue, as delamination between the fibrosa and ventricularis has
been observed in fatigued cusps, likely due to the deterioration of the binding GAG layer [18].
Additionally, the decrease in stiffness may be due to tissue buckling, a local collapse of the tissue
in highly flexed regions [24]. Thus the loss of flexural rigidity is indicative of detrimental
changes in tissue composition and structural integrity.
Valve function and tissue fatigue also affect the biaxial mechanical properties of the
tissue. In contrast to the loss of flexural rigidity, a decrease in material compliance in the radial
direction is observed following fatigue [18]. A significant decrease in radial stretch occurs after
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approximately 200 million cycles, but no corresponding change in circumferential compliance
has been noted. This response may be explained by a stiffening of the collagen fibers and an
overall change in fiber alignment with stress [18]. Again these results indicate that valve
function greatly alters the structural and mechanical properties of the preserved tissue.
The observed changes in tissue mechanics after fixation and fatigue indicate that a purely
mechanical failure mode exists in bioprosthetic valves. The cusps experience high tensile
stresses during closure and flexural stresses during opening. The cyclic nature of valve function
leads to tissue bending and flexural fatigue that causes progressive structural damage, which can
eventually result in cuspal tearing [70]. Explanted valves showing mechanical degeneration with
little to no calcification are frequently collected [94]. However, mechanical fatigue can also act
synergistically with calcification to produce tissue damage. Disruption of the collagen
architecture during flexing may expose new calcium binding sites on the collagen, promoting
further calcification of the matrix [95]. Thus the two main modes of valve degeneration—
calcification and material fatigue—can act together or independently to produce valve failure.

1.5.3.4 Pannus overgrowth
Following bioprosthetic valve implantation, the host tissue grows into the stent and/or
fabric sewing cuff at the valve base. This response is a normal part of healing after surgery, and
a small amount of tissue in-growth is desirable to produce a nonthrombogenic implant surface
[96]. However, abnormal growth of the tissue (pannus) can be problematic if it extends to the
cuspal region. Initial pannus growth is likely initiated by inflammation following surgical injury
and involves fibroblast, myofibroblasts, and endothelial cell infiltration [77]. As the pannus
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develops, collagen is deposited in the deep tissue layers. Eventually the collagen will retract and
alter the tissue structure. Overgrowth of the pannus onto the cusp surfaces leads to cuspal
thickening (Fig. 1.13), increased stiffness, and ultimately stenosis [96].

Figure 1.13: Pannus overgrowth onto the cusps is represented by P‘s [77]

Pannus growth onto the commissures can be especially problematic, as the tissue can
produce attachments between adjacent cusps, fixing them in place and limiting opening [77].
Overgrowth at the commissures also moves the stress concentration away from the commissures
and onto the cusps, possibly resulting in cuspal tears. Furthermore, when the pannus collagen
contracts, valvular insufficiency can result if the cusps also retract. Pannus overgrowth has been
shown to affect both mechanical and bioprosthetic valves, but may be a complication observed
more frequently in stentless valves than in stented, as the stent thickness may provide somewhat
of a barrier between the pannus and the cusps [97].
In summary, the major complications and failure modes associated with bioprosthetic
heart valves are calcification and mechanical degeneration, and to a lesser extent, endocarditis
and pannus overgrowth. Thrombosis of bioprosthetic valves is rare, but the risk of thrombosis
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may be greater for bovine pericardial valves than porcine valves due to the rough surface on the
inflow side of the bovine cusps [77]. The other aforementioned failure modes generally affect
bovine and porcine prostheses with approximately equal frequency, and the average lifespans of
these two valve models are similar. Stentless valves, on the other hand, may be more susceptible
to certain complications than stented valves. Because a greater portion of the aortic wall is
exposed in the stentless model, wall calcification and pannus overgrowth may be more severe
[96]. While design modifications and chemical pretreatments have somewhat mitigated
thrombosis, calcification, and tissue degradation, bioprosthetic valves still lag behind mechanical
valves in terms of durability.

1.6 Percutaneous Heart Valves

Although current replacement heart valves are life-saving devices that have been widely
implanted since their introduction in the 1950s, they still have limitations that constrain their use
to certain patient populations. For example, bioprosthetic heart valves lack the durability
required for use in young, growing patients, while mechanical heart valves necessitate lifelong
anti-coagulation therapy, which may be dangerous in the elderly or patients with bleeding risks.
Additionally, over 50% of bioprosthetic heart valves fail 10-15 years post-implantation [73];
thus, aged patients with failing prostheses may need a second surgery to replace the original
implant. However, the traditional implantation procedure is very invasive, requiring opening of
the chest cavity, induced cardiac arrest, and the use of a heart-lung machine. Patients who are at
high operative risk, such as the elderly or those with serious comorbidities, may be denied valve
replacement, a possibly life-saving surgery. Studies reveal that over 50% of elderly patients with
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aortic stenosis (AS), a disease that is generally treated by valve replacement, are not offered
surgery because the risk of mortality is too great [6, 7]. The proportion of patients with
asymptomatic AS who are denied surgery is even greater; however, asymptomatic AS is not a
benign condition. The EuroHeart survey found that the five year survival rate in patients with
untreated asymptomatic AS is only 38%, compared to 90% in patients that receive aortic valve
replacement [8]. These findings indicate that a need exists for a less invasive valve replacement
option for patients who are not favorable candidates for traditional open heart surgery.
Percutaneous surgery, a minimally invasive technique employed during angioplasty, aortic
aneurysm repair, coronary stenting, and vascular graft placement, is one such option that has
been gaining attention in recent years.

1.6.1 History
Percutaneous intervention for the aortic valve is not a new idea. Balloon aortic
valvuloplasty (BAV) was developed in the 1980s to enlarge the orifice area of stenosed valves
[98, 99]. Similarly to balloon angioplasty, BAV involved threading a balloon through a catheter
to the aortic annulus and expanding the balloon to widen the constricted space. However, BAV
only marginally reduces symptoms and improves orifice area and hemodynamics. In initial
studies, complications were observed in 5-10% of patients, with many suffering from restenosis
within 6-12 months postoperatively [100, 101]. No additional survival benefits were imparted
with BAV, and it was not clinically adopted as a stand-alone therapy. However, much like
stenting after coronary balloon angioplasty, the idea of valve replacement after BAV began to
develop.
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Percutaneous aortic valve replacement (PAVR) was first performed experimentally in
pigs by Andersen et al in 1992 [102]. A porcine bioprosthesis was mounted in a wire stent and
delivered to various aortic sites. Initial results showed good hemodynamic performance of the
percutaneous heart valves (PHVs), but years of design optimization and implantation technique
refinement were necessary before the feasibility of PAVR in humans could be assessed. Ten
years after the first study by Andersen, Cribier et al performed the first successful PAVR in
humans [103]. Following Cribier‘s success, a number of studies of balloon-expandable and selfexpanding PHVs ensued [104-107]. Currently, at least 17 PAVR studies are underway; among
these, two are in clinical trials and at least seven have reached the first-in-man phase [9].

1.6.2 Implantation techniques
The main benefit of PAVR is that it does not require open heart surgery. Thus it reduces
operative risk and patient recovery time. Because PAVR is minimally invasive, it can be
performed on patients that are considered poor candidates for traditional surgery. The basic
surgical technique for PAVR involves threading a catheter to the aortic annulus, performing
BAV to widen the orifice, and then expanding a stent-mounted valve in the annulus [9]. Unlike
traditional bioprostheses, which are sewn in place, PHVs are fixed in place by the radial force
exerted by the stent [108]. The device is visualized and positioned with fluoroscopy,
aortography, and transesophagael echocardiography [9]. Although the heart is not stopped
during PAVR, blood flow must be arrested to prevent the balloon and prosthesis from being
propelled forward during ventricular systole. Flow arrest is achieved by pacing the right
ventricle at 200 beats per minute with a temporary pacemaker [9]. While the steps outlined are
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common to all PAVR methods, variations in the annulus access route are possible. Three
different approaches to PAVR have been considered: antegrade transseptal, retrograde, and
transapical.
The first PHVs were implanted via the antegrade transseptal technique. This procedure
entails catheter access via the femoral vein. The catheter is then threaded up into the right
ventricle, and the septum is punctured to gain access to the left ventricle. The catheter is steered
through the mitral position and up to the aortic annulus, where it is placed antegrade across the
aortic valve [108]. This method is technically difficult and presents a high risk of mitral valve
injury, which could lead to mitral regurgitation, hemodynamic malfunction, and death [104,
107]. Due to the risks of the antegrade transseptal approach, a retrograde technique was adopted.
The retrograde method requires arterial access via the femoral artery. The catheter is
then steered to the aortic annulus retrograde through the aortic arch [106]. The REVIVAL II
clinical study found that the retrograde PAVR technique had an 86% success rate, with a steep
learning curve, as the second 25 patients operated on fared better than the first 25 [109]. While
this approach avoids mitral valve injury and is generally considered safer than the antegrade
method, the retrograde route is not without limitations. First, a highly flexible, deflectable, and
steerable catheter must be used to navigate the tortuous arterial system. Furthermore, patients
with aortic stenosis or failed bioprostheses often suffer from arterial diseases such as
atherosclerosis and vascular and valvular calcification that can narrow the vessels and prevent
delivery of the large-profile prosthesis and catheter [9, 106, 108]. The risk of arterial injury is
high, especially in patients with unusually narrow or tortuous vasculature. These complications
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can preclude a patient from retrograde PAVR. The transapical approach was developed to
overcome the limitations of the antegrade and retrograde methods.
The transapical approach is the method of choice in patients with small or tortuous
femoral and iliac arteries or those with severe peripheral vascular disease [108]. Rather than
accessing the vascular system via the femoral vein or artery, the heart is accessed via a
thoracotomy in the sixth intercostal space. The pericardium is opened and a small puncture is
made in the left ventricle. The catheter is threaded through the left ventricle and to the aortic
annulus, where BAV and device placement are performed as described above. After the valve
has been successfully positioned, the pacemaker is removed, the pericardium and thoracic cavity
are closed, and a chest tube is left in overnight to ensure drainage [108]. In a clinical trial of 59
patients, the transapical route showed a 90% success rate, with a mortality rate similar to the
transarterial approach [9]. This method produces less arterial injury, more direct access to the
aortic annulus, and easier manipulation of the valve as compared to the retrograde method.
Currently choice of surgical technique depends on patient factors and surgeon preference, but a
standardized method may soon be decided upon, as studies to compare patient outcomes between
the two procedures are ongoing [9].

1.6.3 Current designs
1.6.3.1 Clinically tested
Two PHVs, Edwards SAPIEN and CoreValve, have reached clinical trials. The two
models differ in material and also expansion technique. Edwards SAPIEN (previously known as
Cribier-Edwards) made by Edwards Lifesciences Inc. is a balloon-expandable PHV that is
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comprised of three pericardial leaflets. Originally, the leaflets were made of equine pericardium,
but the material was switched to bovine pericardium in second generation models [9]. The
leaflets are mounted on a slotted, stainless steel tubular stent (Fig. 1.14) [103-106, 109]. A fabric
cuff encircles the portion of prosthesis that is implanted proximal to the left ventricle [106]. The
valves are stored in glutaraldehyde and are supplied to the surgeon in the expanded state.
Preparation of the implant is required prior to surgery. A specially-designed crimping device is
used to mount the valve onto the balloon catheter. Orientation of the valve depends on the
approach used—retrograde transarterial or antegrade transvenous [106].

Figure 1.14: Edwards SAPIEN PHV [106]
The Edwards-SAPIEN PHV is available in two expanded diameters: 23 mm or 26 mm.
The heights of these prostheses range from 14.5 mm to 16 mm. Femoral access sheaths between
22F and 24F are needed to accommodate the device. Because of the relatively large profile of
the device, patients with iliac arteries less than 8 mm in diameter are not candidates for
implantation via the transarterial approach [106]. Transapical implantation of the EdwardsSAPIEN has proven to be a successful alternative [9].
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The second PHV in clinical testing is CoreValve (Fig. 1.15) (Medtronic CoreValve,
LLC). CoreValve is also a pericardial, trileaflet valve, but differs from Edwards-SAPIEN in a
number of key ways. The most prominent difference is that CoreValve is self-expandable and
does not require a balloon catheter for implantation. This property is conferred by the stent,
which is made from Nitinol, a shape-memory nickel-titanium alloy that expands at body
temperature. The device can be described by three sections: the lower inlet portion produces a
high radial force upon expansion to push aside the native leaflets; the middle portion of the stent
carries the valve; the upper outlet portion is flared to securely fix the device in the ascending
aorta [9]. In first generation valves, the leaflets were made from bovine pericardium and
required a 25F sheath for transarterial implantation. Second generation valves utilized porcine
pericardium instead, allowing for a 21 F catheter to be used [9]. An alteration in how the tissue
is fixed to the stent in third generation valves has allowed for a device profile of 18F [10, 105].
The small profile enables PAVR to be performed without hemodynamic support, rapid pacing, or
vascular repair of the access site [9]. Second and third generation valves have shown improved
success rates, likely due to the smaller profile and operator technique improvement [10].
However, even with the thinner device, some patients are still not candidates for transarterial
surgery, so transapical studies with CoreValve are in first-in-man trials [110].
CoreValve has not only been used to replace stenotic native valves or degenerated
bioprostheses, but has also been deployed into another CoreValve implant. The duel implant
maintained proper function and hemodynamics at three years follow-up [111], proving the
feasibility of ―valve-in-valve‖ replacement. This is an important feature of CoreValve, as this
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type of secondary replacement is safer than reoperation and may be a treatment option for
degenerative original implants [9].

Figure 1.15: CoreValve PHV [9]

1.6.3.2 First-in-man studies
A number of PHVs have proven successful enough in preclinical studies to progress to
the first-in-man testing phase. The Paniagua valve from Endoluminal Technology Research has
leaflets made from pericardium and is available with a balloon-expandable stainless steel stent or
a self-expanding nitinol stent [112]. The Enable self-expanding valve from ATS is similarly a
pericardial valve in a simple Nitinol tube. Hansen Medical also makes a nitinol valve, the
AorTX. However, this PHV has an additional feature of being repositionable by recapturing the
expanded valve and deploying it a second time. The feasibility of the device and its
hemodynamic properties were proven in eight patients, who temporarily received the AorTX
before undergoing traditional valve replacement surgery [9]. The Direct Flow Valve by Direct
Flow Medical has been tested on both temporary and permanent bases. This unique valve is
neither balloon- nor self-expandable. Rather, bovine pericardial tissue is sutured in a flat
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cylinder between two hydrophilic, coated rings. The device is repositionable and retrievable
before it is permanently fixed in place by inflating the rings with a polymer [113].
Sadra Medical has developed the self-expanding Sadra-Lotus valve. This valve is
repositionable by means of a two expansion phases. The valve first passively expands and
shortens to facilitate positioning, and then actively shortens to increase the outward radial force
and lock it in its final position [114]. Another unique self-expanding PHV is Perceval by the
Sorin Group. This valve has two portions that function independently of each other. The selfexpanding portion of the stent approximates the anatomy of the aortic root and sinuses to
securely hold the device in place, while the non-expandable posts support the pericardial leaflets.
A double layer of pericardial sheets is included to seal the space between the stent and wall and
prevent perivalvular leaks [9].
All of the aforementioned valves have been tested in humans, albeit on a short-term basis
and in a limited number of patients. These first-in-man trials are used as proof-of-concept tests
to show the feasibility of implantation and the generally safety and efficacy of the device. While
initial findings may be promising, large-scale and long-term clinical trials are necessary.

1.6.3.3 Experimental technologies
In addition to the PHVs that have reached clinical and first-in-man testing phases, many
more experimental PHV technologies are being investigated. Some of these have been examined
in animal models, while others are only in the in vitro developmental stage. Heart Leaflet
Technologies is developing a repositionable nitinol valve with an inverted mesh design and antiregurgitation collar (Fig. 1.16a). Zegdi et al constructed a new delivery system for nitinol valves
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that allows the valve to be repositioned and also oriented with the particular angles of the native
valve [115].
Tissue engineering approaches are also being considered for PHVs. However, tissueengineered heart valves made from decellularized tissue often fail due to matrix damage by the
decellularizing process and difficultly in encouraging cells to repopulate the scaffold in vivo
[116, 117]. A new method being studied is in vitro seeding of bioadsorbable scaffolds with
fibroblasts and endothelial cells; this technique has shown initial success in animal models [118].
Finally, nanotechnology is being used to develop new materials with specific properties
tailored to optimal PHV function. The PercValve (Advanced Bioprosthetic Surfaces) utilizes a
nano-synthesized elastic nitinol to construct the frame and leaflets (Fig. 1.16b). Animal studies
showed that this special nitinol undergoes rapid re-endothelialization as early as two weeks after
implantation. Despite the presence of metallic leaflets, thrombosis was not a problem. This data
suggests that the PercValve could potentially offer the durability of a mechanical valve without
the complications of anti-coagulation therapy [9].

A

B

Figure 1.16: Experimental PHV Models: a) Heart Leaflet Technologies; b) PercValve
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1.6.4 Pericardium as a bioprosthetic material
Pericardial tissue has been used almost exclusively in percutaneous heart valves because
it offers the benefit of adaptable designs, rather than being constrained to the natural trileaflet
structure like the porcine aortic valve. The pericardial leaflets can be attached to flexible stents
in a wide array of configurations to produce a valve that can be crimped down and delivered
percutaneously. However, the tissue architecture of bovine pericardium is not identical to that of
the native valve.
Pericardium lacks the three-layered tissue structure—its thickness is almost entirely
collagen-containing fibrosa. The collagen bundles are interspersed with elastin fibers and blood
vessels [Fig. 1.17]. The inner surface of the pericardial sac is composed of a thin layer of loose
tissue called serosa, which lubricates the surface [119]. Pericardial tissue also contains only
small amounts of glycosaminoglycans, indicating that these molecules may play a less critical
role in pericardial mechanics than in heart valve mechanics [120]. Additionally, the tissue
surface of pericardium is different than the cusp surface. One surface of the pericardium is
smooth, while the other is rough since blood and fat have been trimmed away from it. The rough
surface could potentiate thrombosis, so it is generally oriented toward the valve inflow to
increase surface washing [2]. These differences in tissue architecture may affect the durability of
pericardial valves in the long run.

50

Figure 1.17: Cross-section of bovine pericardium [119]

The mechanical properties of bioprosthetic tissue are mainly determined by the
extracellular matrix, especially collagen. Pericardial collagen is less compact than collagen in
the cuspal fibrosa and is almost entirely type I collagen, whereas heart valve cusps contain both
type I and type III collagen [121, 122]. Furthermore, the pericardial collagen is not well
oriented, so the pericardial cusps are not well-adapted for enduring the pressures of cardiac
functioning. A model of pericardial mechanics by Zioupos and Barbenel showed that the
collagen and elastin fibers in each individual layer of the pericardium are directional, but taken
as a whole, there is no dominant direction of fiber alignment in the tissue [123]. Figure 1.18
shows the various orientations of collagen fibers under polarized light. Sacks et al. demonstrated
that different sections of the pericardium have preferential collagen orientations. For example, in
the left frontal region, the circumferential direction predominates, while in the right frontal
region, the apex-to-base direction predominates [124]. The wide variation in collagen direction
makes it difficult to select pericardial tissue that is homogeneous enough to guarantee the desired
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mechanical properties [125]. Highly-aligned collagen in aortic valves helps to transfer stresses
from the cusp to the aortic wall, but pericardium lacks this feature, so stresses accumulate at the
cuspal commissures [5]. Since collagen is less aligned in the pulmonary valve than in the aortic
valve, pericardial prostheses may be better suited for the pulmonary position [9].

Figure 1.18: Planar section of bovine pericardium under polarized light [119]

Although the collagen fibers of pericardium are not as aligned as those of the native heart
valve, pericardial tissue still displays anisotropic mechanical behavior. The circumferential
direction is generally stronger and stiffer but also more extensible than the weaker axial direction
[123]. Sacks et al. demonstrated that the variable mechanical behavior of the pericardium is
consistent with the particular collagen arrangement in various regions of the pericardial sac
[124]. The fiber direction also affects flexural rigidity, as pericardial strips are stiffer when
flexed perpendicular to the local collagen orientation [126]. These results prove that the
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inconsistent, complex nature of the pericardial tissue structure causes regional variations in the
tissue biomechanics, which must be carefully considered when selecting materials for
bioprostheses.
Apart from tissue directionality, the general mechanical properties, such as stiffness, also
vary between heart valves and pericardium. The stress-strain curves for porcine pericardium,
bovine pericardium, and aortic leaflets (circumferential) are shown in Figure 1.19. The slope of
the stress-strain curve represents the modulus, which is a measure of stiffness. For soft tissues, a
three region curve is generally obtained, where the low stress region is dominated by the
response of the elastin fibers and the high stress region is dominated by load-bearing collagen
fibers [127]. The highly extensible region in between the upper and lower moduli represents a
transition in load-bearing capacity [119]. While all of the soft tissues display the same basic
trend, the pericardial tissues have much steeper slopes in the high modulus region, suggesting
they are stiffer than the native heart valve leaflets [119].
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Figure 1.19: Stress strain curve of soft tissues; Porcine pericardium (red) and bovine pericardium
(blue) exhibit similar stiffness, while native aortic leaflets (black) are less stiff. [adapted from
119]

Both bovine and porcine pericardium have been used to construct percutaneous heart
valves [9]. The two tissue types are structurally similar and differ in only a few areas. Porcine
pericardium is slightly thinner than bovine, and its fibrous layer has a more uniform thickness
[120]. These differences led CoreValve to switch from bovine pericardium to porcine
pericardium for its second generation percutaneous valves. The thinner porcine pericardium
allows for a lower profile device that can be delivered through a smaller catheter [9]. However,
the affect of crimping on tissue mechanics and durability have not yet been fully investigated
[108]. Large scale clinical trials are needed to prove if pericardial tissue is sufficient for
constructing successful percutaneous heart valves.
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1.6.5 Complications and failure modes
As with most cardiac bioprostheses, failure modes associated with PHVs include
endocarditis, calcification, tissue degeneration, and pannus overgrowth [108]. Additional
complications are possible due to the method of implantation and specific design features of
PHVs. During percutaneous surgery, serious vascular injury, such as perforation or occlusion, is
a major risk. Incidence of vascular injury has decreased, however, due to lower profile devices
and increased operator experience [105, 106]. Improper positioning of the valve in the left
ventricular outflow tract can lead to mitral valve damage or valve embolization [10, 109]. This
complication can also be mitigated with operator experience, as well as improved visualization
and over-sizing of the stent relative to the annulus [9]. Over-sizing the PHV can also help to
prevent perivalvular leaks, most of which are mild to moderate and do not cause significant
consequences [10, 109, 128].
During PAVR, the native valve is typically not removed, but rather pushed aside by the
stent. The native leaflets can cause coronary obstruction, especially in the left coronary artery.
Recent studies show incidence rates of less than 1% for this complication [129]. However, if
coronary obstruction does occur, percutaneous coronary interventions can be done following
PAVR to correct the problem [130]. New studies are exploring the use of lasers to remove and
ablate the native valve. The development of this technology has been slow because the ablation
products must be filtered and removed to prevent embolism and stroke [131]. Similarly,
atherosclerotic material can also be embolized while threading the catheter through the arteries,
which could also lead to stroke or heart attack [108]. Care must be taken to avoid injuring the
vessels or rupturing plaques and calcific deposits.
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In addition to surgical risks, complications due to the new valve design are also possible.
The expandable stents used in PHVs are similar to coronary stents, and differ greatly from the
non-expandable stents and sewing rings used in traditional bioprosthetic valves. Due to the
outward forces exerted on PHVs to deploy the stents, stent strut fracture can occur [132]. Also,
the PHV stents are held in place by the radial force, and are not sewn into the annulus like
traditional prostheses. Valve mobilization may therefore be possible, although this complication
has not been clinically documented. Furthermore, most PHVs have not been tested beyond a few
years in humans, so it is unclear how crimping and expanding the tissue impacts the long-term
durability of the device [133]. While preliminary clinical data shows promising results for these
new devices, studies are needed to prove their long-term safety and efficacy.

1.7 Bioprosthetic Tissue Fixation Strategies
The major limitation of bioprosthetic valves is durability. One strategy aimed at
improving tissue integrity is crosslinking. Chemical fixation of the bioprosthetic tissue helps to
preserve the structure of the tissue and mask its immunogenicity [36]. While a plethora of
fixation methods have been studied in the past [1, 5, 71, 72], glutaraldehyde remains the
commercial standard.

1.7.1 Glutaraldehyde
1.7.1.1 Glutaraldehyde crosslinking chemistry
Since 1969, glutaraldehyde has been used as a fixative in a number of biomedical areas,
including vascular grafts, ligament replacements, pericardial patches, menisci, and bioprosthetic
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heart valves [134]. Although it has been clinically employed for over 40 years, its mechanisms
of action and effects on the tissue are still not completely understood. Aqueous solutions of
glutaraldehyde contain free aldehydes, monomeric glutaraldehyde, and αβ-unsaturated polymers
of glutaraldehyde [134]. It is generally accepted that glutaraldehyde crosslinks collagen by a
reaction between the aldehyde groups on glutaraldehyde with ε-amine groups on lysine and
hydroxylysine present in collagen [135]. This preliminary reaction results in formation of a nonconjugated Schiff base intermediate. Stable crosslinks form by one of two mechanisms:
combination of two Schiff base intermediates or the addition of a second ε-amine to the double
bond of the aldehyde group of polymeric glutaraldehyde [136]. The conjugated aldehydes in
polymeric glutaraldehyde give rise to stable products, whereas monomeric reaction products are
unstable and hydrolysable [134]. Thus fixation is generally carried out under alkaline
conditions, as polymerization occurs quickly at alkaline pH [134, 136].

Figure 1.20: Schematic of glutaraldehyde crosslink formation [137]
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Glutaraldehyde can reportedly react not only with amines, but also with carboxyl, amide,
hydroxyl, and other protein groups [134, 138, 139]. However, it is most reactive with primary
amines, such as those present in collagen. Therefore, glutaraldehyde is most effective at
crosslinking tissue collagen, but does not preserve other structural components such as
glycosaminoglycans and elastin.
Of the aldehydes, glutaraldehyde is the most effective at crosslinking tissue because it
reacts quickly, can span various distances between proteins, and reacts with a larger number of
amine groups [134]. For instance, formaldehyde has previously been investigated as a fixative
for bioprosthetic heart valves. However, it was found that the crosslinks formed by
formaldehyde are not stable and degrade during storage in saline at 37°C for ten months, whereas
glutaraldehyde-based crosslinks do not degrade under the same conditions [140].

1.7.1.2 Benefits and drawbacks of glutaraldehyde crosslinking
Commercially, tissue is fixed in glutaraldehyde concentrations ranging from 0.2%-0.6%.
Below this range, the tissue is not sufficiently sterilized, and above this range the tissue becomes
too stiff [141]. Glutaraldehyde has several advantageous effects on preserved tissue, such as
reducing biodegradation, increasing biocompatibility, rendering the tissue non-thrombogenic,
and preserving anatomic integrity [134]. However, glutaraldehyde fixation has several
drawbacks as well. Residual glutaraldehyde and unreacted aldehyde groups in implanted tissue
can lead to inflammation, cytotoxicity, calcification, and lack of re-endothelialization. These
negative effects become more pronounced with increasing glutaraldehyde concentration [142,
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143]. Thorough rinsing of the prostheses prior to implantation can reduce cytotoxicity.
Additionally, treatment in L-glutamic acid, glycerol, bisulphate, glycine, or other amino acid
solutions can neutralize unreacted aldehyde groups to improve the biological response to the
implant [134].
The main limitation of glutaraldehyde-fixed tissue is durability. Glutaraldehyde alters the
mechanical properties of the tissue, making it stiffer and less extensible. As previously
mentioned, glutaraldehyde devitalizes the bioprosthetic tissue, eliminating any cellular
mechanisms of matrix remodeling [21]. Thus, the structural integrity of the implant depends on
the quality of the preserved collagen matrix. Glutaraldehyde fixation locks collagen into one
specific confirmation (generally a closed cusp with uncrimped collagen fibers). Because
collagen cannot crimp and align during valve function, tissue buckling often occurs [26, 144].
Furthermore, glutaraldehyde does not stabilize glycosaminoglycans. Loss of GAGs also leads to
increased tissue buckling as well as reduced shearing between tissue layers [27]. Previous work
by our lab has shown that the number of tissue buckles and also the extent of tissue buckling
increase when GAGs are removed from the tissue (Fig. 1.21). This study also confirmed that
GAGs are lost from glutaraldehyde-fixed tissue during tissue preparation, fixation, storage,
fatigue cycling, and in vivo [145].
Not only does glutaraldehyde fail to preserve GAGs, but it does not have the functional
capability to crosslinking elastin either. Elastin is vital to proper valve function. Radiallyaligned elastin in the ventricularis contributes to tissue recoil, minimizing the surface area during
valve opening and stretching radially during closure to provide a large coaptation area [146,
147]. Damage to elastin distends the cusp and causes an increase in stiffness [146]. With no
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regenerative processes possible in glutaraldehyde-crosslinked valves, tissue damage
accumulates, eventually resulting in structural failure, for example cuspal tearing [21].

Figure 1.21: GAG loss increases tissue buckling in glutaraldehyde-fixed tissue; Glutaraldehydefixed cusps (B) exhibit a greater extent of tissue buckling than fresh cusps (A). Removal of
GAGs increases tissue buckling in both fresh and fixed cusps. [27]

Several methods to improve mechanics of fixed tissue have been attempted, including
zero-pressure fixation of bioprosthetic heart valves. This fixation method produces valves that
are initially more flexible, but the valves undergo more collagen remodeling after implantation,
ultimately becoming as stiff as cusps fixed under low pressures [18]. Thus, the benefits of zeropressure fixation may not be maintained post-implantation. Dynamic fixation is a promising
method of improving tissue properties. The valves are subjected to cycling while immersed in
the glutaraldehyde solution. The constant movement prevents collagen layers from being
crosslinked together, improving the shearing ability of the cusp tissue [28]. However, the
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adverse mechanical alterations imposed by glutaraldehyde fixation cannot be completely
abolished, leading researchers to consider alternative fixation strategies.

1.7.2 GAG preservation with neomycin
Studies show that glutaraldehyde fixation causes a loss of glycosaminoglycans during
heart valve harvest, fixation, and storage, and also after fatigue cycling and in vivo implantation
[27, 30, 145, 149, 150]. In the native heart valve, GAGs are mainly present in the spongiosa and
serve several important functions, such as providing hydration, absorbing stresses, filling the
space between the fibrosa and ventricularis, and facilitating smooth sliding between these two
layers [5, 36, 146]. Previous work by our lab has shown that GAG loss has serious
biomechanical consequences, such as increasing tissue buckling, a form of local tissue failure
[27, 148]. Our group has hypothesized that GAG preservation will help to prevent tissue
degradation, thus increasing the durability of the bioprosthesis [148]. Thus, prior studies have
focused on strategies for preserving GAGs in bioprosthetic tissue.
GAG-targeted crosslinking methods, such as periodate and carbodiimide chemistry, were
considered. However, these strategies only partially stabilize GAGs and cannot prevent enzymemediated GAG degradation [145]. Thus, an enzyme inhibitor has been incorporated into the
fixation procedure to help prevent this mode of GAG loss. Neomycin trisulfate, a known
hyaluronidase inhibitor, widely inhibits all hyaluronidases and has amine functionalities that can
be used to chemically attach it to the cusps, thus incorporating it into the tissue [145, 151] (Fig.
1.22). Furthermore, neomycin has a hydrophilic moiety and lipophilic residues that confer
affinity for hyaluronidases to the molecule [151]. Thus, enzymes are attracted to the neomycin
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rather than the carboxyl groups of GAGs, which are the active sites of enzymatic degradation
[145, 152, 153].

Figure 1.22: Neomycin sulfate structure [154]

Previous studies incorporated neomycin into the cusps via carbodiimide chemistry.
Results showed that neomycin inhibited GAG degradation by hyaluronidase, chondroitinase, and
papain [145]. This GAG preservation effect was also observed after one year of storage and
after 10 million and 50 million fatigue cycles [146]. Furthermore, tissue mechanics were also
improved by neomycin, as less tissue buckling was observed in cusps that had received the
neomycin pretreatment [27, 146]. Interestingly, neomycin also seems to prevent elastin
degradation, as neomycin-treated cusps digested with elastase lose less weight than control cusps
[146]. The mechanism behind this nonspecific inhibitory effect has not been elucidated.
While the aforementioned studies were performed using neomycin with carbodiimide
crosslinking, similar results were observed when neomycin was incorporated into the tissue via
simple glutaraldehyde crosslinking (unpublished data). The amine groups on neomycin can react
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with the aldehyde groups of glutaraldehyde to form intermediate crosslinks, thus chemically
binding neomycin to the tissue. Unpublished data from our lab shows that after 400 days in
storage, valves fixed with glutaraldehyde alone lose twice as many GAGs as those pretreated
with neomycin and then fixed with glutaraldehyde. Furthermore, after 50 million fatigue cycles,
neomycin-treated valves show negligible GAG loss while glutaraldehyde controls lose
approximately 15% of GAGs. Thus, pretreating bioprosthetic tissue with neomycin prevents
GAG loss, thereby reducing enzymatic tissue degradation that can lead to mechanical failure.

1.8 Vena Cava as a Bioprosthetic Material
To the best of the author‘s knowledge, vena cava tissue has never before been used in the
construction of a bioprosthetic device. Only one account of the vena cava being used in an
implant was found in the literature. The unique structural properties of the vena cava led one
research group to propose using vena cava has an autologous tissue source for pulmonary valve
replacement. Scharfschwerdt et al [155] hypothesized that vena cava could be fashioned into a
successful pulmonary valve substitute, since its tissue structure is somewhat similar to the native
pulmonary valve, and its endothelial surface may help to prevent thrombosis [156]. In their
preliminary studies, the researchers obtained short cylindrical segments of fresh porcine vena
cava, sutured them into PTFE vascular prostheses, and inverted and sutured the distal portion
into bicuspid or tricuspid-shaped valves (Fig. 1.23). The valves were mounted in a pulsatile flow
chamber, and pressure gradients and valve movements were monitored. Results showed that
bicuspid valves had lower transvalvular pressure gradients but the leaflets did not open
completely. Valve prolapse was also seen in several of the models. The best results were seen in

63

small diameter tricuspid valves, and the research group plans to perform in vivo experiments
with this model. However the authors conclude that the durability and strength of the valves
may be limited by their autologous nature, and homologous or xenograft tissue may be better
suited for valve construction [155].

Figure 1.23: Tricuspid valve fashioned from fresh porcine vena cava [155]

The use of autologous tissue of any sort for valve replacement has many limitations [157161], which is why bioprosthetic valves are currently the standard tissue valves used in aortic
valve replacement. As vena cava has never been utilized in bioprosthetic implants, the
information in the literature about the vena cava structure-function relationship and tissue
mechanical properties is also sparse. The morphology of vena cava tissue is similar to that of all
vascular tissue and is comprised of three layers: intima, media, and adventitia [162]. The intima
lines the vessel lumen and is composed of a single layer of endothelial cells on top of a basement
membrane. The media contains alternating layers of smooth muscle cells and matrix composed
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of collagen and elastin fibers. The outermost tissue layer, the adventitia, is mainly extracellular
matrix components such as collagen and proteoglycans (PGs) with few fibroblasts [162]. A
schematic of the vascular structure is shown in Figure 1.24:

Figure 1.24: Vascular morphologic model [162]

The various tissue layers of the vena cava are exposed to differential stresses, analogous
to how the fibrosa and ventricularis of the heart valve experience differing forces and flexures.
The intima is exposed to shear stresses from flowing blood, as well as compressive and tensile
forces due to blood pressure. The media is mainly in compression and tension due to
hemodynamic loading and the contractile behavior of the smooth muscle cells [162]. The ability
of the vena cava tissue to respond to these forces is likely mediated by the alignment of the
extracellular matrix fibers. In the zero stress state, the fibers in the media are at a 40° to the
longitudinal axis, while the fibers in the adventitia are at a 40° angle to the circumferential axis.
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In the transverse plane of the tissue, the medial fibers are oriented circumferentially. In the
longitudinal plane, the adventitial fibers are directed along the longitudinal axis (Fig. 1.25) [162].
The angular orientation of the ECM fibers reveals spiral wrapping, which is consistent
with other studies [163-165]. The wrapping of the fibers suggests that the mechanical behavior
of the vena cava is dependent on the fibers‘ ability to align in the direction of the applied load
[162].

Figure 1.25: Alignment of vena cava ECM fibers; (A) The medial fibers are oriented
circumferentially in the transverse plane. (B) The adventitial fibers are oriented longitudinally in
the longitudinal plane. (C) Medial and adventitial fibers are at 40° angles to the longitudinal axis
and transverse axis, respectively. [162]

Two studies by Snowhill [162], compared the structure and mechanics of the porcine
vena cava to those of the aorta, iliac arteries, and carotid artery. The proportion of collagen and
smooth muscle cells were similar among the various vascular tissues. However, vena cava was
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found to contain a greater mass density of elastin than the arteries. Furthermore, the vena cava
ECM was determined to be more interconnected than the arteries, as measured by water
adsorption. The amount of water in the ECM is inversely related to the degree of collagen
crosslinking. Since the vena cava had the lowest hydration capacity among the vessels, it was
assumed to contain the greatest amount of crosslinks [162].
Alcian blue staining revealed a very small amount of GAGs in the vena cava as compared
to the other vascular tissues. In general, GAGs and PGs in the vascular tissue are associated with
smooth muscles cells, which may suggest that GAGs are involved in cell-to-ECM binding. Also,
GAGs in heart valves are implicated in shock adsorption and energy dissipation [27]. It is
possible that the vena cava contains fewer GAGs than the arteries because the vena cava is not
exposed to the significant pulsatile pressures that the arterial system experiences [167]. This
hypothesis is consistent with the finding that the vena cava is less viscous than the arteries,
which suggests that it does not require a significant viscous response to dissipate energy and
prevent stress overloads, as it does not experience great pressure variations [166]. Although
GAGs may not play a large mechanical role in the vena cava, it has been suggested that GAGs in
the vena cava hydrate the intimal EC layer and help to prevent thrombogenesis [168].
Further studies by Snowhill considered the elastic and viscous moduli and ultimate
tensile strengths of the various vessels [166]. Since blood vessels generally operate around 1020% strain [169], both the low strain (elastic) region and the high strain (collagen-dominated)
region of the stress strain curve are relevant [171]. In general, the vena cava has a higher
modulus (stiffer behavior) in the low strain region in the transverse direction than in the
longitudinal, which may suggest that the elastin fibers are aligned longitudinally (perpendicular
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to the transverse plane). In the high strain region, the vena cava‘s elastic, viscous, and total
moduli are greater than those of the aorta, carotid, and iliac arteries. The vena cava also has the
greatest ultimate tensile strength among the vessels. The reason for the high strength and
stiffness is not well understood, as the vena cava experiences lower pressures than the aorta, and
thus need not be as resistant to pressure fluctuations [166].
An interesting finding in the Snowhill et al study was that vena cava was the only vessel
examined which exhibited significant strain-rate stiffening, a phenomenon which is also seen in
cartilage, ligaments, and aortic valve leaflets. In the heart valve, stiffening of the leaflets is due
to the close packing of collagen fibers. Shear stiffening has also been observed in crosslinked
pericardium, as crosslinking effectively increases collagen fiber density per unit volume and
reduces fluid motion [170]. Shear stiffening in the vena cava may be explained by the fact that it
exhibits greater interconnectivity, and thus tighter collagen packing, than the other vascular
tissues [171].
Although these results elucidate some of the structural and mechanical differences among
the vasculature, more studies are needed to fully understand the structure and function of the
vena cava. The body of literature surrounding the vena cava is rather small, and most studies
have considered the inferior rather than the superior vena cava. Since the vessel properties vary
so widely among the vascular tree [162] it is possible that these two segments have different
properties. In general, it may be said that the native inferior vena cava has a higher elastin
density, lower GAG content, and greater stiffness and strength than other vascular tissues [162].
However, vena cava has never been used as a bioprosthetic tissue, so its ability to adapt to
different applications and the effects of crosslinking on tissue properties are not yet known.
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CHAPTER TWO
PROJECT RATIONALE

One of the major limitations of aortic heart valve replacement surgery is the invasiveness
of the procedure. Traditional heart valve replacement is performed via open heart surgery, which
is traumatic to the patient and necessitates a long recovery period [6]. Elderly patients and
patients with serious comorbidities are often considered ―high operative risk,‖ and may be denied
a potentially life-saving valve replacement because the risk of mortality is too great [7]. This
limitation of traditional valve surgery must be addressed, as more elderly patients will become
candidates for surgery as the incidence of aortic stenosis and other valvular diseases increases
with the aging United States population [9].

Percutaneous aortic valve replacement (PAVR) is

one technology that has emerged to address the problems with traditional valve replacement.
Percutaneous surgery is a minimally-invasive technique that has proven successful in a
wide array of cardiovascular areas, such as angioplasty, stent placement, and ablation therapy.
Two percutaneous heart valves (PHVs) are currently in clinical trials and many more are in
developmental phases. The two models in the clinical stage and almost all of the models
currently described in the literature utilize pericardial tissue (bovine, porcine, or equine) to
construct leaflets which are mounted onto a stainless steel or nitinol stent [9]. While initial
results are promising, there are still a number of questions which must be answered before the
valves can reach the market. One major factor in the success of the PHV is the quality of the
leaflet material; this aspect of the device will dictate short-term performance and long-term
durability of the implant. The leaflet tissue must be elastic enough to be crimped into a small
diameter stent and expanded in situ. Furthermore, the tissue must be resilient and must not
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permanently deform or incur damage upon crimping. Although pericardial tissue is used in
current PHV models and is also featured in several traditional bioprosthetic valves [9, 77], the
suitability of this tissue for heart valves has been questioned. The structure of pericardium is
dissimilar from that of the native valve leaflet, as pericardium lacks the clearly defined layers
and directionality of valve tissue [123]. Moreover, the structure and mechanical behavior of
pericardial tissue varies regionally over the pericardial sac, which may make it difficult to
construct leaflets with uniform properties [5, 123, 124]. Since load-bearing capability and tissue
extensibility are highly dependent on tissue fiber orientation, the random structure of the
pericardium limits one‘s ability to predict tissue behavior. Thus, pericardial tissue may not be
the ideal choice for PHVs and may limit their success in the long run. However, percutaneous
valve technology is a major breakthrough in valve replacement and has the potential to
revolutionize the entire field, so alternative PHV designs should be considered to optimize
results.
To overcome the limitations of pericardial tissue, our lab proposes utilizing an alternative
tissue source, namely porcine vena cava. Vena cava tissue has a higher elastin density than most
other tissues [162], suggesting that it may be more elastic and flexible, which may enable it to be
more easily crimped and to regain its original configuration upon expansion. Furthermore,
venous tissue is uniformly directional, with elastic fibers aligned longitudinally to allow for
vasomotion and collagen fibers oriented circumferentially to prevent rupture [162]. Thus, it may
be possible to construct uniform leaflets with definite fiber orientations and consistent
mechanical properties similar to those of the heart valve leaflet. The overall goal of this research
project is to assess the feasibility of using vena cava as an alternative to bovine pericardium for
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PHVs. Fresh vena cava and pericardium, as well as glutaraldehyde-fixed samples, will be
examined, as glutaraldehyde is the crosslinker used in all commercial heart valves. Additionally,
neomycin-pretreated tissues will also be investigated, since neomycin has been used
commercially to improve GAG retention and stabilize the mechanical properties of bioprosthetic
valves [27]. To determine if vena cava tissue is a viable option for PHVs, it will be compared to
bovine pericardium in the following areas: structural properties, mechanical behavior, tissue
resilience, and in vivo stability.

2.1 Research Aims
In order to answer the overall project inquiry—is vena cava a better option for PHVs than
pericardium—the following research questions were defined.

2.1.1 Structural properties
Specific aims: How do bovine pericardium and porcine vena cava differ structurally? How do
glutaraldehyde and neomycin affect the structure?
Hypothesis: Vena cava may have more regularly-oriented extracellular matrix fibers than
pericardium, as venous physical properties are directional and differ in the longitudinal and
circumferential planes of the tissue. Because pericardial physical properties can vary locally
over the pericardial sac, it is likely that the pericardial tissue is less organized than the vena cava.
Vena cava may contain a greater proportion of elastin than pericardium since the tissue is highly
flexible to allow for vasomotion. Furthermore, glutaraldehyde crosslinking will stabilize the
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tissue components, and neomycin pretreatment will facilitate GAG preservation in both tissue
types.
Experimental plan: Three groups of porcine vena cava and bovine pericardium will be
investigated: a fresh control, glutaraldehyde crosslinked (GLUT), and neomycin-pretreated
followed by glutaraldehyde crosslinking (NG). Samples will be cut from both the
circumferential and longitudinal directions of the tissue for histological analysis to determine
general morphologic differences. Relative proportions of collagen and elastin will be indirectly
determined by enzymatic digestion of the fresh tissues with collagenage and elastase. The extent
of tissue preservation with the fixation treatments will also be investigated using the
aforementioned enzymes. Collagen and elastin stability will be measured by percent weight loss,
while GAG content will be measured using the hexosamine assay. Finally, differential scanning
calorimetry (DSC) will be used to assess the degree of collagen crosslinking, by measuring the
collagen denaturation temperature of hydrated samples.

2.1.2 Mechanics
Specific aims: Does vena cava tissue offer enhanced mechanical properties as compared to
bovine pericardium? Which extracellular matrix components are important to pericardial and
vena cava mechanical properties? How do glutaraldehyde and neomycin affect the mechanics of
the two tissue types?
Hypothesis: Fresh vena cava tissue may be more compliant than bovine pericardium due to the
high elastin content of the tissue. The stiffness of the vena cava likely differs in the
circumferential and longitudinal directions, and we expect the tissue to be more compliant in the
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direction parallel to elastin fiber alignment. The directional differences in tissue mechanics may
be greater in vena cava than in pericardium due to the more random orientation of pericardial
ECM fibers. Furthermore, elastin likely contributes more significantly to vena cava mechanics
than pericardial because it may be more abundant in the vena cava.
Tissues fixed with glutaraldehyde will be stiffer than fresh samples, as crosslinking inhibits
movement in the tissue. Neomycin-treated samples may be stiffer than glutaraldehyde samples,
as neomycin potentiates additional crosslinks.
Experimental plan: Fresh, glutaraldehyde-fixed, and neomycin plus glutaraldehyde-fixed
samples of pericardium and vena cava will be subjected to uniaxial tension, and the elastic
modulus will be calculated. Fresh samples will also be subjected to GAGase or elastase and then
mechanical tests will be repeated to determine how the ECM components contribute to
directional mechanical properties.

2.1.3 Tissue resilience
Specific aims: Is vena cava tissue better able to withstand compression, such as that exerted by a
stent, as compared to pericardium?
Hypothesis: Vena cava may suffer less tissue damage upon crimping into a stent due to enhanced
flexibility as compared to pericardium.
Experimental plan: Fixed vena cava and pericardium samples will be subjected to compressive
forces similar to those supplied by a stent. The tissue will then be removed and examined for
tears and deformations using general histology and scanning electron microscopy (SEM).
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Additionally, the crimped tissues will be subjected to uniaxial tensile tests in order to determine
if the tissues suffer fiber damage during crimping that affects the mechanical properties.
2.1.4 In vivo stability
Specific aims: Does fixed vena cava calcify to the same extent as fixed pericardium?
Hypothesis: While elastin may render vena cava more flexible and mechanically-suitable for
PHVs than pericardium, the high elastin content may also cause additional calcification of vena
cava.
Experimental plan: Glutaraldehyde and neomycin-plus-glutaraldehyde samples will be implanted
subdermally into male, juvenile, Sprague-Dawley rats. Additionally, some samples will be
treated with ethanol as an anti-calcification measure. After three weeks, the implants will be
removed and examined for calcium content and histological features.
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CHAPTER THREE
MATERIALS AND METHODS
3.1 Materials
Acetyl acetone, p-dimethylaminobenzaldehyde, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), sodium chloride, Tris, ammonium molybdate, L-ascorbic acid, and sodium azide
were purchase from Fisher Scientific (Fair Lawn, NJ). Ammonium acetate, chondroitinase ABC
from Proteus vulgaris, collagenase type VII from Clostridium histolyticum, (D+) glucosamine
HCl, hyaluronidase type IV-S from bovine testes, calcium carbonate, Fast Green FCF, and
neomycin trisulfate hydrate were all purchased from Sigma-Aldrich Corp (St. Louis, MO).
Elastase from porcine pancreas (135 U/mg) was purchased from Elastin Products Company
(Owensville, MO). EM Grade Glutaraldehyde- 8% wt. in H20 was purchased from Polysciences
Inc. (Warrington, PA). Sodium carbonate, alizarin red, and 2-(N-morpholino) ethanesulfonic
acid (MES) were purchased from Acros Organics, (Morris Plains, NJ). Ultra II ultra pure
hydrochloric acid was purchased from J.T Baker (Phillipsburg, NJ). Sulfuric acid was purchased
from EMD Chemicals, Inc. (Darmstadt, Germany). Absolute ethanol was obtained from
Pharmco-AAPER (Shelbyville, KY). Alcian blue was purchased from Anatech, LTD (Battle
Creek, MI). Nuclear fast red and a Verhoeff Van Gieson stain kit were purchased from Poly
Scientific (Bay Shore, NY).
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3.2 Methods
3.2.1 Obtaining and crosslinking xenograft tissue
Fresh bovine pericardium and porcine vena cava were obtained from Animal
Technologies, Inc (Tyler, TX). The tissue was packed in saline and kept on ice and shipped
overnight. All tissues were rinsed in ice cold saline prior to treatment. The pericardial sacs were
cut open along the midline, laid out in a rectangular sheet, and cut into rectangular strips, with
the length of the strip corresponding to the long axis of the rectangular sheet. The vena cavae
were cut along the longitudinal axis and opened up into flat sheets. Rectangular pieces were cut,
with the length of the rectangle corresponding to the longitudinal direction and the width
corresponding to the circumferential direction of the vessel. Within three hours of obtaining the
tissue, several fresh tissue pieces were directly frozen at -4°C or taken immediately for assays,
while the rest were fixed using the following procedures:
GLUT: Tissues assigned to the treatment group designated GLUT were crosslinked
using glutaraldehyde. Pericardial or vena cava strips were placed in 0.6% glutaraldehyde in 50
mM HEPES-buffered saline solution at pH 7.4. The tissue was kept at room temperature. After
a 24 hour incubation in 0.6% glutaraldehyde, the solution was replaced by 0.2% glutaraldehyde.
Tissues were stored in 0.2% GLUT for at least 6 days before assays were performed.
NG: Pericardial and vena cava tissues assigned to the treatment group designated NG
were incubated in 1 mM neomycin trisulfate in 50 mM MES-buffered solution, pH 5.5, for one
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hour at room temperature under constant orbital agitation. Following this incubation, the
neomycin solution was drained and followed by standard GLUT crosslinking, as described
above.
All tissues were fixed in approximately 30 mL of chemical solution per tissue strip.

3.2.2 Structural properties
3.2.2.1 Tissue thickness
The thicknesses of the bovine pericardium and porcine vena cava were assessed, as
thickness of the tissue component of a PHV plays a large role in determining device profile.
Five rectangular strips of fresh, GLUT, and NG pericardium and vena cava were randomly
selected, and four thickness measurements per strip were taken with the Accura Comparator
Stand (Accura Industries, Bombay) for a total of 20 measurements per group. The average
thickness of each tissue type was calculated.

3.2.2.2 Collagen and elastin stability
The tissues‘ ability to resist enzymatic degradation of collagen and elastin was assessed
for fresh, GLUT, and NG pericardium and vena cava. All tissues were rinsed in deionized (DI)
water, lyophilized, and weighed (initial dry weight). Then, the tissues were treated with porcine
pancreatic elastase or Type VII collagenase. Approximately 2 cm² pieces of tissue were
immersed in 1.2 mL of 5.0 U/mL elastase (100mM Tris buffer, 1mM CaCl2, .02% NaN3) or 1.2
mL of 150 U/mL collagenase (50 mM CaCl2, .02% NaN3, pH 8.0). The elastase-treated groups
were incubated at 37°C for 24 hours with constant agitation, while the collagenase-treated groups
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were incubated under identical conditions for 48 hours. The samples were then rinsed in DI
water, lyophilized, and weighed again (final dry weight). The degree of enzymatic degradation
of the tissue was quantified as the percent weight loss, which was calculated by dividing the
difference in final and initial dry weights by the initial dry weight.
3.2.2.3 Differential scanning calorimetry
Differential scanning calorimetry (DSC) was performed on fresh and crosslinked tissues
to assess the collagen denaturation temperature (Td), which is represented by an endothermic
peak in the heating curve [173]. Tissue samples of approximately 7-10 mg were excised, blotted
dry with Kim Wipes, and placed in hermetically-sealed aluminum pans. Samples were heated
from 30°C to 60°C at 5°C per minute, held at 60°C for one minute, and then heated from 60°C to
90°C at 2°C per minute. The resulting heating curves were analyzed using Thermal Analysis
software. The collagen denaturation temperature was recorded at the height of the endothermic
peak, as shown in Figure 3.1.
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Figure 3.1: Example DSC curve; Td is represented by the arrow

3.2.2.4 GAG quantification by hexosamine analysis
Total hexosamine content in the tissue was used as an estimate of total GAG content, as
previously described [27, 146]. The sample tissues were weighed, lyophilized, and hydrolyzed
in 2 mL of 6 M HCl for 20 hours at 95 °C. The samples were then dried under nitrogen gas and
resuspended in 2 mL of 1 M NaCl. The samples were then reacted with 1 mL of 3%
acetylacetone in 1.25 M sodium carbonate solution and incubated at 95 °C for 1 hour. The
samples were then cooled to room temperature and further reacted with 4 mL of absolute ethanol
and 2 mL of Ehrlich‘s reagent (0.18 M p-diemethyl-aminobenzaldehyde, 50% ethanol in 3.0 N
HCl). The samples were incubated at room temperature for 45 minutes to allow for color
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changes, which are indicative of hexosamine quantities, to develop. Then, 300 mL of each
sample was pipetted into a 96-well plate, using D (+) glucosamine solutions (1-200µg) as
controls. Spectrophotometric analysis was performed at 540 nm. All calculated hexosamine
values were normalized to their respective dry tissue weights.

3.2.2.5 Histology
Histological assessment was performed on fresh and fixed tissue, as well as tissues that
were treated with elastase as described above. Representative sections were cut from pericardial
and vena cava tissue strips, along both the longitudinal (length) and circumferential (width)
directions. The tissue samples were fixed overnight in 10% formalin, embedded in paraffin wax,
and sectioned (5 μm sections) for light microscopy analysis. Verhoeff Van Gieson (VVG)
staining was performed to assess the quantity and orientation of elastin fibers. Elastin fibers
were stained black, while collagen was stained red, and all other tissue elements were stained
yellow. Representative images of the sections were taken digitally using a Zeiss Axioskop 2
Plus (Carl Zeiss MicroImaging, Inc., Thornwood, NY) and SPOT Advanced imaging software
(Spot Imaging Solutions; Sterling Heights, MI).

3.2.3 Mechanics
3.2.3.1 Uniaxial tests
Fresh, GLUT, and NG groups were all subjected to uniaxial testing. Additionally, the
behavior of fresh tissue before and after elastase and GAGase treatments were also investigated.
Briefly, the GAGase treatment consisted of incubating 4 cm² tissue strips in 1.2 mL of GAGdegrading enzyme solution (GAGase; 5.0 U/mL hyaluronidase and 0.1 U/mL chondroitinase
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ABC in 100 mM ammonium acetate buffer, pH 7.0). The samples were incubated at 37 °C for
24 hours under constant agitation. Following the incubation, the samples were thoroughly rinsed
in DI water.
For mechanical testing, small tissue strips (approximately 10 mm in length and 3 mm in
width) were excised, the tissue thickness was measured with a caliper, and each sample was
placed between the grips of an MTS Synergie 100 (MTS Systems Corporation; Eden Prairie,
MN). A 10 N load cell was used to apply a tensile force to the tissue samples, and a stress-strain
curve was obtained. TestWorks 4 software (MTS Systems Corporation; Eden Prairie, MN) was
used to calculate the elastic modulus of the sample at both the low modulus and upper modulus
regions of the curve.

3.2.4 Tissue resilience
3.2.4.1 Crimp test
Tissue resilience was assessed by observing the tissue response after being compressed.
The crimp test was performed in collaboration with Paul Ashworth of St. Jude Medical.
Rectangular samples of GLUT and NG pericardium and vena cava were folded back on
themselves twice and compressed under a 35N static load for 30 minutes each. The tissue was
then removed and returned to our lab for further analysis.
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3.2.4.2 Stereomicroscopy
Samples were blotted dry and placed on the stage of the stereomicroscope (Meiji Techno;
Santa Clara, CA). Images were captured with a Spot Insight camera and processed with Spot
Advanced software (Spot Imaging Solutions; Sterling Heights, MI) on both the intimal and
adventitial surfaces of the vena cava and the serosal and fibrous surfaces of the pericardium.

3.2.4.3 Scanning electron microscopy
Scanning electron microscopy (SEM) was used to assess the degree of tissue damage
following the crimp test. Samples were prepared for SEM by rinsing in DI water, dehydrating
through increasing concentrations of ethanol, and critical point dried. The samples were
mounted on the specimen stub with double-sided carbon tape and viewed with the TM3000
(Hitachi; Tokyo, Japan).

3.2.4.4 Uniaxial testing
The crimped tissue was subjected to tensile testing in order to evaluate how crimping
affects tissue mechanics. Uniaxial tensile tests, as described above, were performed on crimped
GLUT and NG vena cava and pericardium. The results were compared to control tissue that had
not previously been subjected to any forces.

3.2.5 In vivo stability
3.2.5.1 Subdermal implantation

82

Subdermal implantation of bioprosthetic tissue in small animals is frequently used to
assess the in vivo responses, such as calcification and inflammation [5]. Small samples
(approximately 2 cm²) of GLUT and NG porcine vena cava and bovine pericardium (n=10) were
excised and rinsed in sterile saline 3 x 30 minutes prior to surgery. Additionally, a second set of
NG porcine vena cava and bovine pericardium samples were pretreated with ethanol (group
NGE), which has been shown to prevent cell-related calcification [5, 33]. The pretreatment
consisted of a 24 hour incubation in 80% ethanol in HEPEs buffer at room temperature with mild
agitation. The samples were then rinsed in sterile saline 3 x 30 minutes prior to surgery. All
animals received humane care in compliance with protocols that have been approved by the
Clemson University Animal Research Committee and NIH. Male juvenile Sprague Dawley rats
(35-40 g; Harlan Laboratories; Indianapolis, IN) were anesthetized by inhalation of isoflurane
gas. Two small incisions (one on each side lateral to the spine) were made on the dorsal side of
the rat. A subdermal pocket was made in conjunction with each incision, and one tissue sample
was placed in each pocket. The incision was closed via surgical staples. Animals were
sacrificed at three weeks using carbon dioxide asphyxiation. The implant and tissue capsule
were explanted and prepared for further analysis. Additionally, small tissue slivers were excised
from four samples per group for histological assessment.

3.2.5.2 Calcium and phosphorus analysis of explants
Tissue samples were immediately frozen on dry ice following the explant surgery. The
samples were lyophilized, weighed, and hydrolyzed in 1 mL of 6N Ultrex II HCl for 20 hours at
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95°C. The samples were then dried under nitrogen gas and resuspended in 1 mL of 0.01 N
Ultrex HCl. The samples were vortexed, and the solution was diluted by 1:50 in Atomic
Absorption Matrix (0.3N Ultrex HCl + 0.5% lanthanum oxide). The calcium content of each
sample was determined by atomic absorption spectroscopy (Perkin-Elmer 3030 Atomic
Absorption Spectrophotometer; Norwalk, CT). The results were normalized by the dry tissue
weight.
For phosphorus quantification, the vortexed solution was diluted by 1:100 in DI water for
a final volume of 1 mL. To this solution, 1 mL of reagent C (2.5% ammonium molybdate with
6N sulfuric acid and 10% L-ascorbic acid) was added, and the mixture was reacted at 37°C for
two hours. The samples were cooled to room temperature, and 250 μl of each was pipetted into a
96-well plate. Spectrophotometric analysis was performed at 820 nm, and the results were
normalized to the dry tissue weight.
Additionally, samples were diluted 1:50 in 10 mL of DI water and brought to Clemson
University‘s Environmental Sciences Laboratory for standard elemental analysis. This set of
results was used to confirm the results obtained in our lab.
3.2.5.3 Histological analysis of explants
Thin slices of tissue were excised from the center of the explants. The specimens were
immediately fixed in 10% formalin for at least 24 hours. The samples were then embedded in
paraffin wax and sectioned (5 μm). Calcium content was analyzed qualitatively by staining the
samples with Alizarin Red and counterstaining with Fast Light Green. Digital images were
obtained and analyzed as described above.
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3.2.6 Statistical analysis
Results are represented as a mean ± the standard error of the mean (SEM). Statistical
analysis was performed by a two-tailed student‘s t-test of unequal variance. Significance was
defined as p < 0.05.

CHAPTER FOUR
RESULTS
4.1 Structural Properties
4.1.1 Tissue thickness
The thickness of fresh and fixed porcine vena cava was compared to that of bovine
pericardium. Fresh vena cava and pericardium had similar thicknesses, 0.184 ± 0.016 mm and
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0.195 ± 0.008 mm, respectively. Results showed that fixation caused an approximately threefold increase in tissue thickness as compared to fresh tissue (Table 4.1). The increase between
fresh and GLUT groups was approximately the same for the vena cava and pericardium (2.91fold and 2.94-fold, respectively). Neomycin treatment did not cause a significant change in
thickness as compared to GLUT tissues. In general, the differences in tissue thickness between
vena cava and pericardium from each treatment group were statistically insignificant (p>0.05).
The only exception was the NG group, in which the vena cava had a thickness of 0.492 ± 0.044
mm, while the pericardium had a statistically greater thickness of 0.616 ± 0.030 mm (p= 0.013).

Porcine Vena Cava

Fresh
GLUT
NG
0.184 ± 0.016 0.536 ± 0.030 0.492 ± 0.044

Bovine Pericardium 0.195 ± 0.008 0.577 ± 0.050 0.616 ± 0.030
Table 4.1: Tissue thickness; Comparison of fresh and fixed vena cava and pericardium; results
given in mm; (n=20)

4.1.2 Collagen stability
Fresh tissue lost a high amount of dry weight after incubation in collagenase (Fig. 4.1).
Fresh pericardium lost significantly more weight than fresh vena cava (74.59% ± 1.008% versus
56.865% ± 3.989%). Glutaraldehyde crosslinking drastically decreased the amount of weight
lost from both tissue types to less than 10% of dry weight. NG-treated vena cava lost less weight
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than GLUT vena cava (1.131% ± 0.449% and 7.072% ± 3.447%, respectively), but the result
was not statistically significant (p= 0.09). NG-crosslinking did not show a similar collagenpreserving effect in pericardium.

Figure 4.1: Collagen stability against collagenase, represented as a percentage of dry tissue
weight loss (n= 6, # indicates difference with FRESH of same species, $ indicates difference
with corresponding pericardium)

Collagen stability was also indirectly assessed by differential scanning calorimetry. The
collagen denaturation temperature of hydrated tissues (Td) was determined by analyzing the
endothermic peak in the heating curve. Fresh tissues exhibited the lowest denaturation
temperatures (62.783 ± 0.183 °C for vena cava and 63.630 ± 0.192 °C for pericardium) (Table
4.2). Crosslinking of the collagen by glutaraldehyde caused a significant increase in Td to 86.383
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± 0.495 °C and 85.487 ± 0.168 °C respectively. NG-crosslinking further increased Td by
approximately 2°C for both tissue types. However, there was no significant difference between
Td for vena cava and pericardium in each treatment group.

Porcine Vena Cava

Fresh
GLUT
NG
62.783 ± 0.183 86.383 ± 0.495 88.393 ± 0.336

Bovine Pericardium 63.630 ± 0.192 85.487 ± 0.168 87.290 ± 0.705
Table 4.2: Collagen stability as represented by thermal denaturation temperature; results given in
degrees Celsius (n= 4)

4.1.3 Elastin stability
Fresh vena cava incubated in elastase lost 35.656% ± 5.470% of dry weight, revealing
that elastin is a major structural component in the vena cava extracellular matrix (Fig. 4.2).
Fresh pericardium, in contrast, lost only 10.513% ± 0.710% of dry weight after elastase
digestion. GLUT-crosslinking did not protect elastin from degradation. NG-fixation, however,
caused a significant decrease in weight loss from both vena cava and pericardium (17.840% ±
4.100% and 4.176% ± 1.948% respectively). The amount of weight lost from the vena cava was
significantly greater than that of the corresponding pericardium for each treatment group.
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Figure 4.2: Elastin stability, as represented by the percentage of dry tissue weight lost following
incubation in elastase (n= 6; $ indicates difference with corresponding pericardium, * indicates
difference with FRESH of same species, and # indicates difference with GLUT of same species)

Histology was used to visualize elastin fibers and confirm elastin preservation by NG.
Fresh tissue sections were taken in both the longitudinal and circumferential directions, which
allowed for the determination of fiber orientation. Figure 4.3A shows that elastin fibers (black)
are oriented along the longitudinal direction. In the circumferential view (Fig. 4.3B) crosssections of elastin fiber bundles are seen, revealing that elastin is oriented perpendicularly to the
circumferential plane. Figure 4.3C-D show corresponding images of bovine pericardium. In
pericardium, the elastin fibers and not aligned in any one direction; thus the tissue appears
intensely black because elastin is oriented in all directions and in all planes.
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Figure 4.3: VVG stain of FRESH tissues for elastin: (A) Porcine vena cava, longitudinal; (B)
Porcine vena cava, circumferential; (C) Bovine pericardium, longitudinal; (D) Bovine
pericardium, circumferential. 100X magnification

Tissue sections were also stained prior to and following elastase treatment (Fig. 4.4).
Histology confirms that all of the elastin was lost from the fresh vena cava after elastase
treatment (Fig. 4.4D). GLUT-crosslinked tissue also shows a significant loss of structure after
elastase, although few elastin fibers are still visible (E). The entire tissue structure is better
preserved with NG treatment and more elastin fibers are obvious (F). Similar trends are seen in
the pericardial tissue (Fig. 4.5).
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Figure 4.4: Effect of elastase on fresh and fixed porcine vena cava: (A) Fresh, untreated; (B)
GLUT, untreated; (C) NG, untreated; (D-F) corresponding fixation group after elastase
digestion; Longitudinal plane at 100x magnification.
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Figure
4.5: Effect of elastase on fresh and fixed bovine pericardium: (A) Fresh, untreated; (B) GLUT,
untreated; (C) NG, untreated; (D-F) corresponding fixation group after elastase digestion;
Longitudinal plane at 100x magnification.
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4.1.4 GAG content
To measure the GAG content of heart valves, the hexosamine assay is commonly used, as
GAGs contain two components—a hexosamine sugar and an uronic acid molecule. In the
porcine vena cava tissue, there was no significant difference in hexosamine content among fresh,
GLUT, and NG samples (Fig 4.6). In contrast, bovine pericardium showed trends similar to
those of heart valves, with GLUT tissue containing fewer GAGs than fresh, and NG conferring a
GAG-preserving effect [146]. However, the results express absolute amount of hexosamines.
Biologic tissue contains non-GAG-related hexosamines; the quantity of these hexosamines is
known for heart valve cusps and generally subtracted from hexosamine results to obtain pure
GAG content. As the amount of non-GAG-related hexosamines is not known for vena cava and
pericardium, only the relative quantity of GAGs in the tissue can be represented.
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Figure 4.6: GAG content as represented by hexosamine content of tissue; (n=6; * indicates
difference with Fresh of same species; $ indicates difference with GLUT of same species; %
indicates difference with corresponding pericardium)

4.2 Mechanical Properties
4.2.1 Uniaxial tension
In order to determine how extracellular matrix components contribute to tissue
mechanics, uniaxial tensile tests were performed on fresh vena cava and pericardium in both the
longitudinal and circumferential directions prior to and following elastase and GAGase
incubations. Since heart valves operate in both the elastin (lower modulus) and collagen (upper
modulus) regions of the stress-strain curve, elastic moduli for both slopes were calculated.
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Porcine vena cava was significantly less stiff in the longitudinal direction than the
circumferential (Fig. 4.7). Removing the elastin from the tissue via elastase incubation caused a
significant increase in the elastic modulus, especially in the longitudinal direction. Additionally,
GAG removal caused a larger increase in stiffness in the circumferential direction than the
longitudinal, suggesting that GAGs play a larger role in the circumferential mechanics.
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Figure 4.7: Elastic moduli of fresh porcine vena cava: (A) Lower modulus; (B) Upper modulus;
(n=6; * indicates difference with corresponding untreated tissue)
Fresh bovine pericardium was significantly stiffer than fresh vena cava, with moduli at
least twice those of vena cava in all orientations. Elastase treatment caused a large increase in
the lower modulus in both tissue directions (Fig. 4.8). GAG removal did not affect the lower
modulus in the circumferential direction, but caused a decrease in stiffness in the longitudinal
direction. Conversely, GAGase treatment resulted in an increase in the upper moduli in both
directions. These results are also summarized in Table 4.3.

Lower Modulus (kPa)
Untreate Elastase GAGase
d

Upper Modulus (kPa)
Untreated Elastase GAGase

PVCCirc.

15246.9
362.68± 968.05± 1156.76± 7173.09± 5945.68 6±
16.90
36.91
41.50
243.21
± 330.80 182.76
PVC10626.9
Long.
54.72±
1825.88 149.91±
2390.62± 0±
3323.12
2.80
± 267.60 6.85
132.66
189.71
± 269.50
B
BP26238.8 43328.0
Circ.
477.13± 5518±
475.45±
18256.98± 8±
7±
23.77
162.13
16.39
401.92
247.07
380.84
BP25935.5
Long.
41923.6 2±
2132.54 7485.33 1133.56± 23601.28± 9±
397.341
± 160.79 ± 379.44 12.64
375.02
374.25
9
Table 4.3: Elastic moduli of fresh porcine vena cava (PVC) and bovine pericardium (BP) in the
circumferential (Circ.) and longitudinal (Long.) directions

96

A

B

Figure 4.8: Elastic moduli of fresh bovine pericardium: (A) Lower modulus; (B) Upper modulus;
(n=6; * indicates difference with corresponding untreated tissue)

In clinical practice, bioprosthetic tissue is treated with a fixative, so the mechanical
effects of GLUT and NG crosslinking were also investigated (Fig. 4.9). Bovine pericardium was
significantly stiffer than porcine vena cava in all treatment groups, except GLUT in the
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circumferential direction. The pericardium was especially stiff in the longitudinal direction as
compared to the vena cava, indicating that the longitudinal alignment of elastin fibers in vena
cava greatly lends itself to the tissue compliance.
Fixation causes a significant increase in tissue stiffness. GLUT tissues were stiffer than
fresh samples. NG further increases the stiffness over GLUT, likely because of additional
crosslinks formed within the tissue.

A
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B

Figure 4.9: Effects of fixation on elastic moduli of porcine vena cava (PVC) and bovine
pericardium (BP); (A) Lower modulus; (B) Upper modulus; (n=6; All differences between PVC
and BP are significant (p < 0.05) except GLUT in the circumferential direction)

4.3 Tissue Resilience
4.3.1 Stereomicroscopy
Fixed vena cava and pericardium were subjected to compressive forces similar to those
applied by a stent. Figure 4.10 shows the results of crimping porcine vena cava. The control
tissues in the left column are highly textured, with the adventitia (C and D) being rougher than
the intima (A and B). After crimping, directional striations are visible on the intima of GLUT
and NG vena cava. New tissue markings are not readily apparent on the adventitial surface of
the crimped tissue, as the surface of the controls was rather rough.

99

Figure 4.10: Stereomicroscopy images of control and crimped vena cava; A) Intima, GLUT
control; B) Intima, NG control; C) Adventitia, GLUT control; D) Adventitia, NG control; E)
Intima, GLUT crimped; F) Intima, NG crimped; G) Adventitia; GLUT crimped; H) Adventitia;
NG crimped; Each scale line represents 1 mm
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Similar images were captured of control and crimped bovine pericardium. The serosa
surface of the pericardium is perfectly smooth (Fig. 4.11 A and B). After crimping, very faint,
thin markings can be seen on the surface (E and F). The outer layer of the pericardium (C and
D) is rougher; thus it is difficult to spot tissue damage caused by crimping (G and H).
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Figure 4.11: Stereomicroscopy images of control and crimped bovine pericardium; A) Serosa,
GLUT control; B) Serosa, NG control; C) Outer, GLUT control; D) Outer, NG control; E)
Serosa, GLUT crimped; F) Serosa, NG crimped; G) Outer; GLUT crimped; H) Outer; NG
crimped; Each scale line represents 1 mm
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4.3.2 SEM

The surfaces of the crimped tissues were observed with scanning electron microscopy to
further detect any defects. The adventitial surface of the control vena cava and the outer surface
of the control pericardium were again very rough, and additional indentations and striations were
impossible to detect. However, the smooth intima and serosa exhibited some surface
modifications after crimping. The intimal surface of the control vena cava samples (Fig 4.12)
are generally smooth with small grooves spanning uniformly across the surface. After crimping,
the GLUT sample had many new indentations and deep ridges. The NG samples also exhibited
new grooves on the surface; however the NG tissue was significantly less damaged than the
GLUT tissue. Similar results are seen in the bovine pericardial tissue (Fig 4.13). The serosa
surfaces of the GLUT and NG control pericardium samples are smooth with uniform surface
ridges. The GLUT tissue exhibited cracks and fiber damage after crimping, while the NG tissue
remained relatively smooth.
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Figure 4.12: SEM images of intimal surface of control and crimped vena cava; A) GLUT
control; B) GLUT crimped; C) NG control; D) NG crimped; 150x magnification
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Figure 4.13: SEM images of the serosa of control and crimped bovine pericardium; A) GLUT
control; B) GLUT crimped; C) NG control; D) NG crimped; 150x magnification

4.3.3 Mechanical properties of crimped tissue
Following crimping, the vena cava and pericardium were subjected to uniaxial tensile
tests. The results were compared to uncrimped controls in order to determine how the
compressive forces experience during crimping affect tissue fibers and mechanical properties
(Fig. 4.14).
In the circumferential direction, crimping caused a significant increase in the lower
elastic modulus of all tissue groups. Additionally, the GLUT-fixed bovine pericardium became

105

stiffer than the corresponding vena cava after crimping. The effects of crimping were not
obvious in the upper modulus in the circumferential direction, as only GLUT-fixed PVC was
significantly stiffer than the control in this group.
The trends in mechanical behavior in the longitudinal direction differed slightly from the
circumferential behavior. After crimping, a significant increase in the lower elastic modulus was
again seen among all tissue groups. However, the pericardium became much stiffer than the
vena cava, reaching a lower elastic modulus of 13,212.03 ± 846.23 kPa for NG tissue, while NG
vena cava had a modulus of only 3,036.43 ± 808.33 kPa after crimping. Considering the upper
modulus, the crimped pericardium again increased in stiffness as compared to the controls, but
the difference was not as great as for the lower modulus. The upper elastic modulus of the vena
cava decreased in the longitudinal direction, resulting in vena cava tissue that was significantly
less stiff than pericardial tissue for both tissue groups.
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A

B

C

D

Figure 4.14: Elastic modulus of tissue after crimping; A) Lower modulus, circumferential; B)
Upper modulus, circumferential; C) Lower modulus, longitudinal; D) Upper modulus,
longitudinal; (n=6; * indicates difference with control tissue; $ indicates difference with crimped
BP tissue)

4.4 In vivo stability
4.4.1 Calcium and phosphorus content
Subdermal implants were used to study the mineralization tendency of the tissues. The
juvenile rat model was selected, as juvenile rats exhibit accelerated calcification [5]. GLUT and
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NG pericardium and vena cava were studied. Additionally, another group of NG tissue was
treated with ethanol (NGE) as an anti-calcification therapy.
After 3 weeks of implantation, GLUT-fixed vena cava calcified significantly less than
pericardium (Fig. 4.15). However, neomycin treatment led to an increase in mineralization of
the vena cava, and the difference in calcium content between NG vena cava and pericardium is
not significant (p= 0.246). Ethanol treatment resulted in an 82.69% decrease in the calcium
content of the bovine pericardium, but only a 50.90% decrease in calcification of vena cava. The
difference between calcium content of the NGE vena cava and pericardium was not statistically
significant (p = 0.106) due to large variability among the various rats.

Figure 4.15: Calcium content of subdermally implanted tissue; (n = 10 (GLUT and NG); n = 6
(NGE);* indicates significant difference with corresponding bovine pericardium (BP) group)
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Phosphorus content is often used as a complement to calcium data, as mineral deposits in
heart valves are generally composed of calcium phosphate. Trends similar to those in the
calcium data are observed in the phosphorus results for the various tissue groups (Fig 4.16).

Figure 4.16: Phosphorus content of subdermally implanted tissue; (n = 10 (GLUT and NG); n =
6 (NGE)* indicates significant difference with corresponding bovine pericardium (BP) group)

Additionally, the Ca:P molar ratio for each sample group was calculated (Table 4.4), as
this statistic provides information about the organization of the calcium phosphate in the tissue.
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Vena Cava

Pericardium

GLUT 1.37± 0.039 1.33± 0.007
NG

1.42± 0.012 1.35± 0.003

NGE

0.93± 0.094 0.64± 0.102

Table 4.4 Ca:P molar ratio of rat subdermal implants

4.4.2 Histology
Calcium content was also viewed histologically via the Alizarin red stain, which stains
calcium red. Light green was used as a counter stain. The histological results complement the
aforementioned quantitative data. Denser clusters of calcification are observed in the pericardial
tissue than in the vena cava (Fig. 4.17). However, after ethanol treatment, almost no calcium is
apparent in the bovine pericardium, while the vena cava still exhibits bands of calcium deposits
throughout the tissue.
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Figure 4.17: Alizarin red histology; Calcium content of subdermally implanted porcine vena
cava (PVC) and bovine pericardium (BP) is represented by red staining, while background tissue
is stained green; A) GLUT PVC; B) NG PVC; C) NGE PVC; D) GLUT BP; E) NG BP; F) NGE
BP; Images taken at 100x
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CHAPTER 5
DISCUSSION
While percutaneous technology is revolutionizing the field of replacement heart valves,
these new devices are not without limitations, the most important of which is device profile. The
ability to access the aorta via a catheter is largely determined by the diameter of the catheter that
is required. Tortuous vasculature or narrow atherosclerotic arteries can only be accessed with
small diameter catheters [9, 106, 108]. First generation PHVs were too wide for transcatheter
delivery in many patients and necessitated transapical delivery instead. However, the transapical
approach requires a thoracotomy and puncture of the left ventricular, so it is inherently more
invasive than the transcatheter route [108]. In order to produce a smaller diameter valve,
Medtronic CoreValve switched from bovine pericardium to porcine pericardium, which is
reportedly thinner than bovine [9]. Additionally, they altered their tissue fixation method in such
a way as to manufacture a smaller PHV.
Another possible method to decrease device profile is to use a highly elastic alternative
tissue source. Vena cava is denser in elastin fibers than other blood vessels and may be a good
option for PHVs. However, vena cava has not previously been used as a bioprosthetic tissue,
and its structural properties are not fully characterized in the literature. The aim of this project is
to understand the tissue structure and matrix properties of porcine vena cava in order to predict
how such tissue might behave in this application.
All of the current bioprosthetic percutaneous heart valves are composed of either porcine
or bovine pericardial tissue [9], and bovine pericardium is also used to construct traditional
bioprosthetic heart valve implants. Any alternative tissue source will have to perform at least as
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well as bovine pericardium in order to be a desirable option for PHVs. Therefore, porcine vena
cava was compared directly to bovine pericardium in all of our studies. The structure,
mechanics, tissue resilience, and in vivo behavior of vena cava were investigated in order to
assess the feasibility of using the tissue in bioprosthetic PHVs.

5.1 Tissue Structure
The profile of a PHV is highly related to tissue thickness, as the bioprosthetic tissue must
be folded into the supporting stent [9]. The tissue thickness of fresh and fixed vena cava was
compared to that of bovine pericardium. Fresh vena cava and pericardium were similar in
thickness, both measuring about 0.20 mm. The glutaraldehyde fixation process causes an
increase in thickness, as crosslinks cause the tissue to contract in the longitudinal and
circumferential directions. While GLUT vena cava and pericardium were also similar in
thickness (0.54 ± 0.03 mm and 0.58 ± 0.05 mm respectively), NG vena cava was significantly
thinner (0.49 ± 0.03 mm) than NG pericardium (0.62 ± 0.03 mm). A possible explanation of this
phenomenon may be that pericardial tissue contains a greater proportion of collagen fibers than
vena cava. The addition of neomycin may enhance GLUT crosslinking of those fibers to cause
additional contraction and a greater increase in thickness. The native heart valve has a thickness
of approximately 0.605 ± 0.196 mm [172], so the thicknesses of fixed vena cava and bovine
pericardium are anatomically compatible with the application. Although vena cava and
pericardium were generally similar in thickness, we have also hypothesized that the vena cava
may be more flexible, a factor which could also help reduce device diameter.
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The mechanical properties of bioprosthetic heart valves are largely dictated by the
extracellular matrix. In native heart valve leaflets, circumferentially-aligned collagen fibers in
the fibrosa support loads during cyclic functioning, while radially-aligned elastin fibers in the
ventricularis allow for extensibility and coaptation [172]. Additionally, glycosaminoglycans in
the spongiosa help to hydrate the tissue and adsorb shock. Thus, the composition and orientation
of tissue extracellular matrix components are crucial to proper valve function. It is known that
bovine pericardium contains planar fibers, specfically collagen type I and a small amount of
elastin [176]. Vena cava, in contrast, has a high elastin density, helically-oriented elastin fibers
in the media, and circumferentially-aligned collagen fibers in the adventitia [162]. We further
examined the extracellular matrix components in the tissue quantitatively using enzyme
digestion studies. Fresh and fixed tissues were digested in elastase and collagenase, and the
percent weight loss was calculated. It was assumed that fresh tissue offered no enzymatic
resistance, so the percent weight loss represented the weight fraction of each tissue component.
Fresh bovine pericardium lost significantly more weight after collagenase than did porcine vena
cava (74.59± 1.01% and 56.86± 3.99% respectively). This result suggests that the pericardial
extracellular matrix is more collagen-dense than vena cava ECM. Fixation with glutaraldehyde
greatly enhances collagen stability, decreasing the percent weight loss to less than 10% in both
tissue types. GLUT forms stable crosslinks with collagen through a Schiff base reaction between
the aldehyde group and the amine group on the lysine and hydroxylysine residues of collagen
[27]. The crosslinks help prevent enzymatic degradation of the collagen fibers. NG did not
improve collagenase resistance in pericardium, but reduced percent weight loss to 1.13± 0.45%
in vena cava tissue. While neomycin is a hyaluronidase inhibitor, it has been shown to affect
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collagen and elastin preservation as well [146]. Neomycin likely increases the crosslinking
density of the GLUT-fixed tissue, providing steric hinderance for enzyme diffusion into the
tissue. Differences in collagen structure between vena cava and pericardium may affect how the
neomycin is incorporated into the GLUT crosslinks in each tissue, which would subsequently
affect how the crosslinked fibers are affected by the enzyme.
The main component of the heart valve extracellular matrix is collagen, a structural
protein which provides the strength needed to withstand cyclic loading [5]. The collagen
molecule is a triple helix of glycine, proline, and hydroxyproline. Upon heating, the collagen
helices transition to random coils. This process of collagen denaturation is endothermic and
irreversible [173]. Differential scanning calorimetry (DSC) measures the collagen denaturation
temperature (Td) by monitoring the heat flow in the tissue sample while heating at a set rate.
Collagen denaturation is represented as an endothermic peak on the heating curve, as heat is
taken in to break bonds and unwind the collagen helix. The Td‗s for fresh vena cava and
pericardium were 62.78 ± 0.18 ºC and 63.63 ± 0.19 ºC, respectively. GLUT fixation
significantly increased Td, as GLUT-based crosslinks between collagen increase the stability of
the fibers. The thermal denaturation temperature of the GLUT vena cava and pericardium is in
agreement with previously reported values of 88.3 ± 0.56 ºC in GLUT porcine aortic valves [92].
The denaturation temperature of NG tissue was slightly, but significantly, greater than that of
GLUT. Neomycin induces additional crosslinks in the tissue. Crosslinking pulls the fibers
closer together, reducing the number of possible molecular configurations. Thus, the entropy is
reduced and the Gibb‘s Free Energy increased. More energy is needed to induce a change of
state, resulting in a higher Td [174]. While DSC confirmed that collagen is indeed protected by
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GLUT and NG fixation, the method was not sensitive enough to detect subtle differences in
collagen content between pericardium and vena cava.
Elastin is the second major component of the tissue extracellular matrix. In the native
heart valve, radially-aligned elastin fibers provide tissue extensibility that allows for coaptation
during valve closure. Furthermore, elastin provides the recoil to return the tissue to its
compressed state between loading cycles [175]. Studies have shown that elastin fibers are vital
to proper valve mechanics, and elastin damage in the native heart valve results in tissue
elongation, reduced radial extensibility, and increased stiffness [175]. Therefore, preservation of
elastin is vital to bioprosthetic tissue mechanics. Previous literature reports that the vena cava is
more elastin-dense than other vascular tissues. Elastase digestion was used to quantify the
proportion of elastin in fresh tissue. Fresh vena cava lost significantly more weight (35.10±
5.47%) after elastase treatment than did bovine pericardium (10.51± 0.76%), which suggests that
elastin constitutes a larger proportion of vena cava ECM. GLUT fixation did not render the
tissue more enzyme resistant, as GLUT does not crosslink elastin fibers [175]. However, NG
treatment led to a significant decrease in percent weight loss in both tissue types. This result was
also confirmed histologically, as more elastin fibers were visible in NG tissue after elastase
digestion than in fresh and GLUT tissue. Neomycin has previously been shown to inhibit
elastase-mediated elastin degradation of bioprosthetic heart valve cusps [146]. This result again
supports that increased crosslinking density in NG tissue impedes enzymatic access to the tissue
fibers, thus decreasing enzymatic degradation of the tissue. Over time, elastin damage by
elastase increases the shock loading on collagen fibers, rendering the bioprosthesis less durable
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[177]. Thus the addition of neomycin to the GLUT crosslinking procedure may help to preserve
the tissue structure and mechanical properties in vivo.
In addition to elastin content, the orientation of the elastin fibers was also studied.
Verhoeff van Gieson staining was performed to visualize the elastin in the tissue. It has been
suggested that the elastin fibers are wrapped around the vena cava helically in the longitudinal
direction [162]. Our results show that in fresh vena cava, the elastin fibers were clearly oriented
in the longitudinal direction, while cross-sections of the fibers were seen in the circumferential
plane. The longitudinally-oriented elastin imparts elasticity to the vena cava along the length of
the vessel. Conversely, no clear fiber orientation was apparent in the bovine pericardium. The
fiber directionality varies regionally in pericardium, and also may vary between planes [123].
The non-uniformity and unpredictability of the fiber orientation causes great variability in
mechanical properties across the pericardial tissue, making it difficult to construct a consistent
heart valve [124, 125]. In the native heart valve, the elastin fibers are aligned to impart radial
extensibility to the cusps. Because the vena cava consists of highly aligned fibers, a more
consistent valve may be constructed which better mimics the fiber structure of a native valve.
Glycosaminoglycans play a large role in heart valve mechanics by hydrating the tissue,
dissipating energy, and facilitating shearing between tissue layers [146]. While the role of GAGs
in heart valve mechanics is well understood, their function in other vascular tissues, such as the
vena cava, has not been elucidated. The literature suggests that GAGs may help to lubricate the
vena cava‘s intimal layer [168]. Similarly, GAGs provide hydration and lubrication to the serosa
layer of the pericardium [120]. GAGs are composed of a hexosamine sugar and a uronic acid
molecule. The hexosamine assay [145] was performed on vena cava and pericardial tissue. The
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vena cava had no significant difference in hexosamine content among fresh, GLUT, and NG
tissue. However, the pericardium had more hexosamines in fresh and NG tissue than in GLUT, a
result that has also been found in heart valves [145, 146]. It is known that the porcine heart
valve contains tissue hexosamines that are not related to GAGs. Previous research has
determined that 90 ug of non-GAG-related hexosamines are present in the heart valve [149, 150].
However, the quantity of non-GAG-related hexosamines in vena cava and pericardium is not
known. Thus the amount of hexosamines cannot be taken as an absolute measure of GAG
content. However, when viewed as a relative measure of GAGs, certain conclusions may be
drawn. GAGs are lost during tissue preparation and GLUT fixation, and GLUT-fixed cusps
typically contain fewer GAGs than fresh tissue [27, 146]. Moreover, since neomycin has been
shown to be effective at preserving GAGs [145, 146], it is expected that the NG group will
contain more GAGs than the GLUT tissue. However, the amounts of hexosamines in fresh,
GLUT, and NG vena cava were equal; thus most of these hexosamines are likely non-GAGrelated. Indeed, it has been reported that the quantity of GAGs in the vena cava is quantitatively
undetectable [167]. However, as expected, the hexosamine content of NG bovine pericardium is
greater than that of GLUT tissue. Thus, GAGs are detectable in pericardium, and NG treatment
effectively preserved GAGs in pericardial tissue. Although GAGs are vital to native heart valve
mechanics, it is unclear if the lack of GAGs in vena cava will be detrimental to valve
performance. Fatigue cycling and in vivo studies are needed to determine if the vena cava can
withstand constant flexure and shearing without a significant amount of GAGs to adsorb shock
and dissipate energy in the tissue.

5.2 Mechanical properties
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Extracellular matrix fiber orientation plays a large role in biologic tissue mechanics [172,
176]. Elastin fibers provide flexibility and extensibility in the tissue direction parallel to their
alignment, whereas load-bearing collagen fibers impart strength and stiffness along their length
[2, 5, 21]. Blood vessels, such as the vena cava, are composed of circumferentially-aligned
collagen fibers to allow the vessel to withstand the forces from pulsatile blood flow [162].
Previous studies also suggest that the elastin fibers helically wrap along the longitudinal axis of
the vena cava [162]. Thus, there is a great contrast in extracellular matrix orientation between
the circumferential and longitudinal axes of the vena cava, which should correspond to
substantial mechanical differences between the two directions. In contrast, the collagen and
elastin fibers in the pericardium are not well-aligned and vary regionally, making the
pericardium less uniform and predictable mechanically [5, 9, 123-125].
For many biological tissues subjected to tensile testing, the stress-strain curve contains
two regions: a lower modulus region that is dominated by elastin fibers and an upper modulus
region that is dominated by the collagen response [119, 127]. Indeed the stress-strain curves for
the vena cava and pericardium displayed the expected two-region behavior. Tensile testing of
fresh tissue samples confirmed histological findings regarding fiber orientation. The lower
elastic modulus of fresh vena cava was significantly lesser in the longitudinal direction than the
circumferential, indicating longitudinal alignment of the elastin fibers. The upper modulus was
greater in the circumferential direction due to the circumferentially-aligned collagen fibers.
Following elastase treatment, the longitudinal lower modulus increased more than 30-fold, while
the circumferential lower modulus increased only about 2.5-fold. Therefore, disruption of the
elastin fibers causes a massive increase in the stiffness along the fiber direction, while only a
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small increase is seen in the perpendicular direction. In the circumferential direction, the upper
modulus decreased with elastase treatment, as fewer perpendicular fibers were present to impede
motion in this direction [176]. Thus, the alignment of the elastin fibers plays a critical role in the
vena cava tissue mechanics in the longitudinal direction.
Conversely, the longitudinal moduli of the fresh bovine pericardium were greater than the
circumferential moduli. Following elastase treatment, the lower modulus increased by 11.5
times in the circumferential direction and 3.5 times in the longitudinal. This result suggests that
the elastin fibers of the pericardium tend to be aligned more toward the circumferential direction,
which would allow outward extensibility of the pericardial sac as the heart beats. However, the
pericardial elastin fiber alignment is not as profound as that of the vena cava. The upper moduli
of the fresh pericardium also did not differ as starkly in the circumferential and longitudinal
directions as those of the vena cava, confirming a more random orientation of collagen fibers in
the pericardium. The varied collagen alignment serves to provide strength to the pericardium in
multiple directions, as the sac must withstand a number of different forces, including outward
tension and torsion during the cardiac cycle [123]. However, this diverse alignment causes
variations in mechanical properties that are not ideal for constructing a mechanically stable heart
valve.
The role of GAGs in pericardium and vena cava tissue mechanics are not well
understood. Thus, fresh tissues were treated with GAG-degrading enzymes, and the tensile
response was examined. GAGase treatment caused a significantly larger increase in the upper
and lower moduli in the circumferential direction than the longitudinal in the vena cava. This
result indicates that GAGs may be associated with the circumferentially-aligned collagen fibers
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and may help to facilitate movement and shearing between the fibers, which is major function of
GAGs in heart valve mechanics [5]. Similary, GAGase had a significant effect on the upper
modulus of the pericardium in the circumferential direction, also suggesting an association
between GAGs and collagen in the pericardium. GAGs in the pericardium may therefore
provide lubrication and facilitate shearing between collagen fiber layers during torsion.
Direct comparison of the corresponding moduli between the fresh vena cava and
pericardium revealed that the pericardium is stiffer than the vena cava in all tissue orientations.
The difference is especially significant in the upper modulus, likely due to the greater collagen
content of the pericardium. A denser collagen network in the pericardial tissue impedes fiber
movements and causes the tissue to be less compliant.
The tissue fixation process has also been shown to have a significant effect on tissue
mechanics [27]. Chemical crosslinking of the collagen matrix improves tissue stability, but also
hinders fiber movement, leading to increased tissue stiffness [21, 26, 144]. GLUT fixation
increased the moduli of both the vena cava and pericardium, due to crosslink formation.
Addition of neomycin to the crosslinking procedure (NG) led to a further increase in stiffness, as
neomycin is incorporated into GLUT crosslinks, thereby increasing the crosslink density. While
the moduli of the two tissue types were only modestly different in the circumferential direction,
the pericardium was enormously stiffer than the vena cava in the longitudinal direction, a result
which was exacerbated by GLUT and NG crosslinking. The higher collagen content of the
pericardium was more affected by crosslinking, resulting in very high elastic moduli for fixed
pericardium. As GLUT and NG do not crosslink elastin [146], the vena cava was able to retain
much of its flexibility, especially in the lower modulus region. While the vena cava did increase
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in stiffness during crosslinking, it remained at least twice as compliant as the pericardium in the
longitudinal direction after fixation. Increased stiffness following crosslinking is cited as a major
contributor to bioprosthetic valve mechanical failure [27]. Use of vena cava in valve
construction may therefore improve prosthesis durability by enhancing bioprosthetic tissue
flexibility.

5.3 Tissue resilience
The main advantage of percutaneous heart valves is their ability to be implanted without
open chest surgery. The unique PHV design allows the entire valve to be crimped into a small
diameter and delivered via a transcatheter route to the aortic position [9]. However, this design
feature also raises concerns about the integrity of the crimped tissue [108]. Stents are crimped
under large compressive forces. Subjecting the tissue to excessive loads prior to implantation
may alter the mechanical properties, damage the implant surface, or harm extracellular matrix
fibers. Thus, the response of the vena cava and pericardium to compression was studied. The
tissues were folded three times and compressed under a 35N load, similar to that applied during
stent crimping. After 30 minutes of loading, the tissue was removed and the surface structure
and mechanical properties were compared to uncrimped controls. Stereomicroscopy and SEM
images showed that both the vena cava and pericardium controls contained a smooth and a rough
surface. The smooth surface of the vena cava corresponds to the intima and the rough surface to
the adventita [162], whereas the serosa of the pericardium is smooth and the outer surface is
rough [5]. Stereomicroscope images of the surface revealed faint parallel striations on the
intimal side of GLUT and NG vena cava, indicating that the crimping process caused dents in the
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tissue surface. SEM images further showed that the intima of GLUT vena cava was greatly
affected by crimping, but that NG tissue was more resistant to surface damage. Similarly, faint
dents, markings, and fiber tears are apparent on the serosa of the pericardium, with more damage
to GLUT than NG. However, both the adventitia and outer pericardium are already too rough
and textured to distinguish any new indentations with either stereomicroscopy or SEM. The
results suggest that crimping in a stent alters the surface topography of the vena cava and
pericardium, and pressure from the stent struts may cause damage to the tissue surface. A rough
surface on the inflow surface of the valve can potentiate thrombosis formation [5], so the smooth
tissue surfaces should be oriented inward and the crimping process carried out in such a way as
to minimize compressive pressure from the stent struts on the inner surface.
NG tissue exhibited less surface damage than GLUT tissue. Neomycin enhances
preservation of elastin and collagen in the tissue during fixation and storage [146]. The NG
group contains a denser network of crosslinked fibers, which may be better able to withstand
stress during tissue crimping. As a result, the NG tissue appears to be more resilient and better
suited for constructing a PHV.
Loading has been shown to cause changes in tissue mechanics [172, 176]; thus the elastic
modulus of the crimped tissue was compared to that of the controls. Crimping increased the
lower elastic modulus for all tissue types, suggesting that the compressive force stiffened the
tissue. The lower modulus is dominated by the response of the elastin fibers [127]. The increase
in lower modulus was especially evident in the circumferential direction. Applied stress causes
fiber realignment in the direction of the force to help the tissue bear the load [176]. The elastin
fibers may have realigned circumferentially to increase the stiffness in that direction. The
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increase in lower modulus in the longitudinal direction is small for the vena cava, and is likely
due to the elastin fibers uncrimping under the load, causing slight stiffening of the tissue [172].
The increase in stiffness in the longitudinal direction is greater for the pericardium, possibly
because the elastin fibers are less aligned and do not all react to the load uniformly by realigning
to the same degree in the same direction.
The upper elastic modulus is dominated by collagen fibers, which uncrimp and realign in
response to an applied load [127, 172, 176]. The upper elastic modulus in the circumferential
direction for most of the tissue groups did not show a significant increase after compression.
However, the GLUT vena cava had a slight increase in modulus in this orientation. Conversely,
in the longitudinal direction, the vena cava exhibited a decrease in the upper elastic modulus
while the pericardium exhibited an increase. The results suggest that the collagen fibers of the
vena cava realigned in the circumferential direction, causing stiffening. The tissue is less stiff in
the longitudinal direction because fewer fibers are available to bear the load. For the
pericardium, the increase in upper modulus in the longitudinal direction was small, suggesting
that some of the randomly-oriented collagen fibers realigned longitudinally. In general, the
crimped vena cava samples were less stiff than the corresponding pericardium samples,
especially in the longitudinal direction. After crimping, the vena cava maintained its mechanical
directionality, exhibiting greater compliance in the longitudinal direction than the
circumferential. Thus, the crimping process does not negate the mechanical benefits offered by
the vena cava.

5.4 In vivo behavior
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One of the major failure modes of glutaraldehyde crosslinked bioprosthetic heart valves
is calcification. Calcium deposits form hard nodules on the cusps or aortic wall that can lead to
cuspal tears or stenosis [77]. Calcification is often cell-related, as glutaraldehyde devitalizes
cells, eliminating active calcium regulation processes [88]. Upon exposure to body fluids,
intracellular calcium levels in the bioprostheses rise dramatically, and calcium deposits form on
the phospholipid-rich membranes and organelles [87]. Extracellular matrix proteins such as
collagen and elastin have also been noted as secondary nucleation sites [89]. The calcium
deposits eventually aggregate to form hard, sharp nodes that can stiffen or perforate the tissue
[88]. A number of anti-calcification strategies have been studied [5]. Ethanol pretreatment of
the valves specifically targets cellular-based calcification. Incubating the heart valve in at least
80% ethanol solution prior to implantation extracts phospholipids and cholesterol from the
tissue, thus removing those nucleation sites of calcification. Ethanol also causes a change in the
collagen confirmation that renders the collagen less susceptible to mineralization [148].
Calcification can be studied in vivo using the juvenile rat subdermal implant model,
which offers accelerated mineralization kinetics and is often used as a screening method for anticalcification techniques [5]. GLUT, NG, and NGE vena cava and pericardium samples were
implanted into juvenile Sprague Dawley rats. After three weeks, the implants were removed and
analyzed for calcium content. GLUT vena cava exhibited significantly less calcification than
GLUT pericardium, possibly due to differences in cell density between the tissue types.
Addition of neomycin caused a significant increase in mineralization of the vena cava, but did
not significantly alter the pericardium calcium content. The dramatic increase in the NG vena
cava is likely due to its high elastin content, as neomycin preserves elastin fibers, thus making
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the tissue more susceptible to elastin-mediated calcification. Furthermore, ethanol pretreatment
was more effective at reducing pericardial calcification (82.69% decrease) than vena cava
calcification (50.90% decrease). The vena cava extracellular matrix contains a higher proportion
of elastin than that of the pericardium. Thus, elastin-mediated calcification likely accounts for
the difference in ethanol efficacy. In the native heart valve, ethanol pretreatment reduces cuspal
calcification, but does not prevent mineralization of the aortic wall due to its high elastin content
[92]. The aortic valve cusps are approximately 10% elastin, while the aortic wall is 50% elastin
[177]. Similarly, the high elastin density of vena cava, approximately 35%, renders the tissue
more prone to ECM-based calcification than pericardial tissue. Histological findings confirmed
that GLUT and NG pericardium contained dense clusters of calcium deposits, while NGE
pericardium exhibited almost no calcium staining. NGE vena cava, in contrast, displayed bands
of calcium deposits along its length, perhaps corresponding to the longitudinally-aligned elastin
fibers. Since ethanol does not sufficiently prevent calcification of the vena cava, an alternative
anti-mineralization strategy will have to be implemented if the tissue is to be used clinically.
Additionally, the Ca:P molar ratio of the mineralized explants was calculated, as different
types of calcium phosphate contain varying proportions of these elements [179]. Pure
hydroxyapatite (HAP), which comprises bone, has a Ca:P ratio of 1.67, while precursor phases
such as octocalcium phosphate (OCP) and dicalcium phosphate dehydrate (DCPD) have ratios of
1.33 and 1.00, respectively. HAP formation is thought to be a process of phase transitions from
transient forms of calcium phosphate, such as DCPD, to OCP, and finally to mature, stable HAP.
Furthermore, the transition phase can be determined by crystal structure, as DCPD is large and
irregular, while OCP is plate-like, and HAP is composed of small crystals [179]. Based on the
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calculated Ca:P ratios, the calcium phosphate deposits in GLUT and NG vena cava and
pericardium are likely in an intermediate phase between OCP and HAP. Ethanol treatment
causes a change in the calcification behavior, resulting in deposits that contain less calcium and
are predominantly phosphorus. In NGE vena cava, the deposits are likely similar to DCPD;
however, in the NGE pericardium, the ratio is only 0.64± 0.102, indicating that these deposits
may be even less thermodynamically stable than DCPD.
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CHAPTER 6
CONCLUSIONS AND RECOMMENDATIONS
6.1 Conclusions
In recent years, a major trend in medicine has been a drive toward minimally invasive
procedures. This movement is especially important to cardiology, where open chest surgeries
account for high mortality rates and limit the pool of patients who are offered certain procedures.
Aortic heart valve diseases such as aortic stenosis are becoming more prevalent in the United
States as the population ages. However, traditional valve replacement surgery requires open
chest surgery with cardiopulmonary bypass, a procedure which is too risky to perform on the
elderly or patients with comordibities. As a result, many patients are denied a possibly lifesaving procedure. The advent of minimally invasive valve replacement surgery has the potential
to revolutionize the field of heart valves. Two percutaneous heart valves, which are delivered
transcatheter to the aortic root and held in place by a stent, are currently undergoing clinical trials
and may receive FDA approval within the next year or two. However, these devices have certain
limitations which must be overcome before they can reach the market. A unique aspect of PHVs
is that they must be crimped into a stent to a diameter small enough for transcatheter delivery
through narrow, stenotic, or tortuous vasculature. While certain design modifications to the first
generation GLUT-fixed bovine pericardium PHVs have allowed for percutaneous delivery, the
affects of crimping on the tissue have yet to be elucidated. We have proposed an alternative
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tissue source, vena cava, which may be more compliant and resilient than pericardium, and may
offer enhanced properties to PHVs.
The results of our studies clearly show that vena cava has several advantages over
pericardium. While the two tissues are equal in tissue thickness and collagen stability, the vena
cava has a significantly higher elastin content, a factor which imparts enhanced flexibility to the
tissue. Moreover, the elastin and collagen fibers in the vena cava are highly aligned, resulting in
mechanical directionality and consistency. In contrast, the pericardium contains more collagen
and less elastin, and the extracellular matrix fibers are more randomly oriented, leading to a
stiffer tissue with less predictable mechanical properties. While the pericardium stiffens
drastically after GLUT and NG fixation, the vena cava retains much of its flexibility. After
crimping, both the GLUT vena cava and pericardium exhibited surface damage, while the NG
tissues were less affected. Furthermore, the vena cava experienced a less significant change in
elastic modulus after crimping, suggesting that the tissue may be more resilient to the
compressive forces imparted by a stent.
While the vena cava offered several structural and mechanical benefits over the
pericardium, certain features of the vena cava produced ambiguous results. Both the vena cava
and pericardium contain significantly fewer GAGs than the native heart valve, with the vena
cava comprising the least amount. GAGs are vital to native heart valve mechanics, serving to
lubricate, adsorb shock, and facilitate shearing between tissue layers. However, given the
differences in tissue structure and extracellular matrix composition between the vena cava and
heart valve, it is unclear whether the lack of GAGs in the vena cava will be detrimental to PHV
function. Additionally, the vena cava exhibited confounding in vivo behavior. While GLUT
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vena cava calcified less than GLUT pericardium, the addition of neomycin caused a dramatic
increase in vena cava mineralization, but an insignificant increase in pericardium mineralization.
Ethanol treatment helped to attenuate the calcification of the pericardium, but did not greatly
reduce that of the vena cava, likely due the high elastin content of the vena cava. Under the
tested treatments, the vena cava calcifies too heavily in vivo, and an elastin-targeting
anticalcification treatment will be necessary to overcome this problem.
Thus, we have shown that vena cava improves upon current PHVs by enhancing
structural orientation, mechanical properties and tissue resilience. Furthermore, NG treatment of
the vena cava preserves elastin fibers and reduces tissue surface damage after crimping. While
certain features such as GAG content and calcification tendency still need clarification, it appears
that vena cava is a viable alternative tissue source for use in PHVs.

6.2 Recommendations
The studies described here represent initial work in assessing the feasibility of using vena
cava in PHVs. The structural properties, mechanics, and calcification potential of fresh and
fixed vena cava have been characterized. However, in order to draw conclusions about the
behavior of the vena cava in a replacement valve, further work is needed. First, the structurefunction relationship must be fully characterized. Specifically, the quantity and role of GAGs
should be determined. The uronic acid assay or fluorophore-assisted carbohydrate
electrophoresis can be used to quantify the amount of GAGs in the fresh vena cava.
Furthermore, transmission electron microscopy (TEM) can be used to identify the position of
GAGs among the extracellular matrix fibers. Additional mechanical testing, such as cyclic
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loading and creep tests, should be carried out prior to and following GAGase treatment of fresh
and crosslinked vena cava to evaluate the role of GAGs in the viscoelastic response of the tissue.
In order to be clinically useful, in vivo mineralization of the NG vena cava must be
reduced. Future studies should focus on identifying an anticalcification treatment to minimize
elastin-mediated mineralization. Trivalent metal ions, such as aluminum or ferric chloride, have
been used in the past for this purpose. Long term rat studies should investigate several
anticalcification options, including combination therapies which target both cellular and elastinbased calcification. Additionally, the types of calcium phosphate crystals in the implants should
be further characterized. The size and shape of the crystals can be observed with TEM and
compared to the Ca:P ratios to identify the types of deposits present.
After fully assessing the tissue properties of the vena cava, a model heart valve should be
constructed from the NG tissue. Several current bioprosthetic valves and PHVs use bovine
pericardium that has been cut and sewn into stents to create trileaflet valves. Vena cava should
be similarly shaped and formed into a valve, and the prototype should undergo cyclic fatigue.
Such testing will reveal how the tissue responds to continual loading and unloading. Following
fatigue testing, the valves should be evaluated by DSC, TEM, tensile testing, and biochemical
analysis in order to fully understand the effects of pulsatile valve function on the tissue structure.
Finally, a true percutaneous valve should be constructed from the vena cava. The design
should be modified until the lowest profile configuration is reached. Crimping the tissue inside
of the stent and deploying it will help to further characterize the tissue resilience.
All of the aforementioned studies should be undertaken using NG bovine pericardium as
a control. The performance of the vena cava can then be compared to an accepted standard, and
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the potential benefits and disadvantages of replacing the pericardium with vena cava clearly
assessed.
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